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ABSTRACT 
This dissertation evaluates the effects of Saskatchewan’s Prevention Program for 
Cervical Cancer (PPCC) in its first decade of operation (2000-2011). Launched in August 2003, 
the PPCC is an organized population-based program that encourages participation in Pap smear 
testing within timeframes consistent with medical screening guidelines. All eligible women for 
whom the PPCC database does not have a test result are mailed a letter of invitation to 
participate in screening, including women who turn 18 or who are new residents of 
Saskatchewan. Once Pap test results are in the database, clients are mailed results and reminder 
letters to return to screening at the recommended time. Clients whose first test result is normal 
are recalled one year later. After two consecutive normal test results, recall occurs after three 
years. Clients with an abnormal-low result are recalled after six months and those clients with a 
test result of abnormal-high are referred to a physician for immediate follow-up within six weeks.  
This study has the following three objectives: (1) Evaluate overall, age-specific, and age-
standardized screening participation rates in Saskatchewan before and after the introduction of 
the PPCC and ascertain change patterns over time. (2) Evaluate whether the participation rate is 
affected by urban/rural residential location and socioeconomic status of eligible women living in 
urban areas. (3) Examine the pattern of follow-up visits for women before and after the 
introduction of the PPCC.   
The Saskatchewan Cancer Agency’s administrative cervical cancer screening database 
includes Pap tests provided to female clients between 20-69 years of age from 2000 to 2011.  
Spline analysis was used to identify patterns of change over time before and after the 
implementation of the PPCC and survival analysis was employed to investigate patterns of 
follow-up visits. Results show that the introduction of the PPCC initially increased the three-year 
rolling participation rates. Participation reached its zenith (64.7%) in 2002-2004, and fell 
thereafter reaching 60.9% in 2009-2011; a rate even lower than before the PPCC started (62.7%). 
Spline analysis confirmed the statistically significant upward and downward trends both before 
and after peak participation was reached in the 2002-2004 period.  
Younger women were more likely to participate in Pap smear testing than older women, 
although older women were more likely to comply with follow-up after abnormal-low results. 
Women living in urban areas were about 10-20% more likely to take the test than those living in 
rural areas. Women in lower income quintile areas were significantly less likely to take the test 
iii 
than those living in higher income quintile areas with approximately a 3% difference in 
participation at each income quintile level.  
Survival analysis found that subsequent screening visits for those who had already 
participated can be roughly divided into the following two groups: women who chose to undergo 
annual testing regardless of how many normal test results they received (i.e., essentially 
disregarding clinical guidelines) and women who followed no clear schedule.  
A significant finding of this study was that the ratio of invitation to result letters received 
by clients served as a predictor for participation rates. The invitation letter strongly encourages 
women to screen. As 95% of the screen results are normal, most result letters direct women to 
return to screen after a three-year interval as stated in clinical guidelines. When the PPCC started, 
most women received invitation letters. Over time, an increasing proportion of women received 
result letters because most of them had already been screened multiple times. Given that 
participation rate is calculated for all eligible women, this ratio of the two letter types suggests 
that participation would initially increase and then decrease over time.  
The findings of this study support previous research on the impact of socioeconomic status 
(SES) on cancer screening participation. The model proposed in this study partially explains both 
the initial increase and the subsequent decrease in participation rate. It can serve as a working 
hypothesis to be tested with data from other similar screening programs. 
These results show that the PPCC had a positive impact, especially in the first few years of 
its operation and that its operational protocol can be modified to increase the overall participation 
rate in the future. These results also suggest that measures to improve participation be 
implemented, especially among the unscreened or among women from lower SES 
neighbourhoods or rural areas.   
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Age-standardized Rate: An age-standardized rate represents the number of new clients that 
would attend screening had the age distribution of the study population in a particular time 
period been the same as the standard population (1991 Canadian population). 
 
Covered Population: The covered population is based on eligibility for health insurance 
benefits in Saskatchewan. All residents of Saskatchewan are included except members of the 
Canadian Armed Forces, members of the Royal Canadian Mounted Police, inmates of federal 
prisons and people not yet meeting the residency requirement. 
 
Crude Rate: A rate that is not adjusted for other factors (such as age). 
 
Incidence: The number of new cases of a disease diagnosed each year. 
 
Lead Time: The time gained in treating or controlling a disease when detection is earlier than 
usual. 
 
Mortality: In this analysis mortality is the primary cause of death reported on death certificates 
(as cervical cancer). 
 
Participation Rate: Percentage of eligible women in the target population (20-69 years of age) 
with at least one Pap test in a three-year period. 
 
P-value: The probability that a test statistic (e.g. a standardized incidence ratio) would be as 
extreme or more extreme than the one observed, because of chance, if the groups were really 
alike.   
 
Ratio: The value obtained by dividing one quantity by another. 
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Retention Rate: Percentage of eligible women re-screened within three years after a negative 
Pap test in a twelve month period. 
 
Sojourn Time: The interval between detectability at screening and clinical presentation of a 
condition. 
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CHAPTER 1  
INTRODUCTION 
1.0 Introduction  
According to the 2012 World Health Organization report, “cancer is a leading cause of 
morbidity and mortality, with 14 million new cases and 8 million cancer-related deaths in 
2012.”1 Among female cancers worldwide, cervical cancer was ranked fourth after breast, lung 
and gastro-intestinal cancers with over half a million of new cases and 266,000 deaths in the 
same year.
1 
 
As a secondary prevention method, screening is considered a lifesaving approach because it 
detects the presence of disease before it manifests itself through observable symptoms. Therefore 
several screening tools for the most common and detectable cancers have been developed and 
tested to enhance early tumour detection and intervention. In the case of cervical cancer the wide 
spread use of the Papanicolaou (Pap) test worldwide has contributed to substantial reductions in 
incidence and mortality of this disease.
2,3,4,5 
Women who are not screened regularly or who have 
never been screened are more frequently diagnosed with invasive cancer often at an advanced 
stage.
6,7,8,9 
Beyond the potential for avoiding deaths, cervical cancer screening may reduce 
morbidity since treatment for earlier-stage cancers is often less aggressive than that for more 
advanced-stage cancers. In addition, the Pap test identifies pre-cancerous cervical lesions before 
they develop into invasive cancer. Usually invasive cancer grows slowly and takes anytime from 
years to decades.
10
 Thus, participation and repeat screening can reduce both cervical cancer 
mortality and incidence at the population level.
2,11
  
In Canada, cervical cancer screening efforts date back to the introduction of a screening 
program British Columbia in 1949. Incidence and mortality rates have decreased substantially in 
the past 50 years due to the cervical cancer screening.
8,12
 About two decades later Miller et al 
demonstrated that screening significantly reduced mortality of cervix and uterine cancers among 
30-64 year old Canadian women over a ten-year period (1960-62 to 1970-72).
13
 Another study 
using data from 1931 to 1984, revealed a decline in age-specific mortality rates among four of 
eight age groups considered. The greatest decline was among 55 to 64 year old women.
14
 Across 
Canada, screening has had an impact on declines in mortality and incidence after controlling for 
2 
the age structure of the population. From 1981 to 2005, age-adjusted rates per 100,000 
population in mortality (3.9 to 1.8) and incidence (13.9 to 7.1) dropped almost 50%.
15,16
 
This trend is evident in Saskatchewan as well. Prior to the introduction of opportunistic Pap 
smear testing in the 1960s, cervical cancer was the third most common cancer among 
Saskatchewan women and accounted for 11% of all female cancers (in 1950-54).
17
 After the Pap 
test was introduced, age-standardized incidence rates for invasive cervical cancer per 100,000 
women aged 35-64 went down from 46 in 1963 to 11 in 1973. Age-standardized mortality rates 
per 100,000 women aged 30-64 years decreased from 14 in 1960-62 to 9 in 1970-72.
18
 In the 
period 1997-2001, cervical cancer did not even rank among the top six female cancers diagnosed 
in the province.
17 
 
This decrease in cervical cancer incidence and mortality slowed down during the 1990s. 
While the reasons for this downward trend are not clear, it is possible that opportunistic 
screening did not reach all segments of the target population. Recognizing the need for a more 
comprehensive approach the Government of Saskatchewan introduced the Prevention Program 
for Cervical Cancer (PPCC) in 2003 at the Saskatchewan Cancer Agency (SCA) for women 
between 18-69 years of age.  
Organized cervical cancer screening through the PPCC differs from opportunistic screening 
in two important aspects. First, the PPCC systematically recruits and reminds women to attend 
screening through invitation and reminder letters. Next, the PPCC invites women based on 
recommended clinical guidelines to reduce the screening frequency among women who have 
already received multiple screenings with consecutive normal test results. The PPCC’s key 
outreach method is sending invitation and recall letters to every eligible woman in Saskatchewan. 
It was expected that this outreach method would significantly increase the overall participation 
rate and that women would follow-up on their Pap test as recommended.
19,20,21
  In the published 
literature, the use of invitation letters have been shown to significantly increase organized 
screening participation rates
2,22,23,24
   
In reality, Pap smear participation rates initially increased, from 62.3% in 2001-2003 to 64.7% 
in 2002-2004. However, the participation rate in the next few years showed no further gain and 
even dropped in 2005-2007 to 63.8%.
25
 Given that practically all age-eligible women in 
Saskatchewan receive a letter inviting them to screen with the PPCC, it was not clear why a third 
of them did not participate in screening as recommended. Also, as invitation and recall letters are 
3 
sent to clients repeatedly, it was expected that overall participation and recall rates would 
gradually increase over time. There is an increasing recognition in the literature that the 
determinants of screening participation and repeat Pap testing are complex, multifaceted and 
interrelated.
26,27 
It has also been suggested in the literature that women from a lower 
socioeconomic status would be less likely to attend screening.
28,29 
 
Although the PPCC was started twelve years ago, apart from routine reporting of 
participation rate a comprehensive evaluation of its effects on cervical cancer screening efforts in 
the province has not been done. This dissertation aims to fill some of these gaps by answering 
the following questions: (1) Have participation and retention (repeat testing) rates increased after 
the introduction of the PPCC? (2) Do residents in urban areas have different participation rates 
compared to their rural counterparts? Further, does socioeconomic status play a role in 
influencing cervical cancer screening participation among urban residents? (3) How have clinical 
guidelines recommending repeat Pap tests three years after two consecutive normal Pap tests 
influenced client screening behaviour? The findings from this dissertation are not only relevant 
to Saskatchewan, but may provide an insight into screening participation and repeat Pap testing 
trends across Canada. This dissertation is guided by the Quality in the Continuum of Cancer Care 
(QCCC) model
30
 which is based on the Behavioural Model of Utilization developed by 
Anderson
31,32
  to examine different aspects of the PPCC as well as factors influencing 
participation at the following two levels: system (e.g. clinical guidelines) and at the individual 
level (e.g. urban or rural residence, neighbourhood income as a proxy for individual 
socioeconomic status).  
1.1 Organization of thesis 
Following the introduction describing gaps in knowledge about population–based screening 
programs (chapter 1), the literature review (chapter 2) provides an overview of the history and 
practices of cervical cancer screening programs worldwide. In particular, the Saskatchewan 
PPCC is introduced and a guiding framework for this research is discussed. In the methodology 
chapter (chapter 3) data sources used and methods to investigate specific objectives are outlined 
and described in depth. The study results (chapter 4) including participation and retention rate 
trends, participation by urban and rural areas of clients residence, influence of neighbourhood 
income on participation and retention as well as a multivariable model of all the factors are then 
presented. Next, the main findings (chapter 5) will be compared and contrasted with other studies. 
4 
In addition, this chapter assesses the strengths and limitations of the study, and recommends 
future research questions and strategies to enhance PPCC participation and client/physician 
compliance with repeat testing guidelines.  
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CHAPTER 2  
LITERATURE REVIEW 
2.0 Some definitions 
Screening can have different connotations and it is important to define what screening 
means in the context of this dissertation. The verb “to screen” is defined as “to sift by passing 
through a screen” by the Oxford English Dictionary.33 Screening in health services is defined as 
the systematic and rapid application of a test, examination or procedure for the identification of a 
disease or defect among asymptomatic individuals.
34
 
 Screening tests sort out apparently well persons (asymptomatic individuals) who are more 
likely to have the disease from those who probably do not. The goal of cancer screening is to 
detect pre-cancerous lesions or cancer at an early stage, before symptoms appear. Screening tests 
have been successfully used in the general population and impacted downward invasive cancer 
incidence and mortality rates.
34
 The key points of a screening test that enable it to be successful 
include the following: (1) the test should be valid (e.g. both specific and sensitive); (2) reliable 
(gives consistent results when retested; no random errors); (3) acceptable by the public (in terms 
of discomfort, hassle, cost of obtaining the test); (4) provide good yield – number of positive 
cases identified in the population;  (5) acceptable cost– benefit (compare costs avoided due to 
early detection of the disease against cost of the screening); (6) Follow-up services are available 
i.e., a plan is needed to deal with positive results.
35
 When abnormal tissue or cancer is found 
early, it may be easier to treat or cure. By the time symptoms appear, the cancer may have grown 
and spread. This makes the cancer harder to treat or actual cure.   
Cervical cancer is ideal for screening because of its natural history and a long and variable 
preclinical phase before the symptoms of the disease become apparent. This preclinical phase is 
that portion of the disease’s natural history during which the disease is potentially detectable but 
unrecognized. The interval between when the disease can be detected but is still asymptomatic 
and when the disease symptoms become clinically apparent is called the sojourn time. Delay 
time and lead time are two components of the sojourn time. Delay time is the period of time 
before screening detects cancer. Lead time is the interval between the time of disease detection 
through screening and time of disease recognition in the absence of screening. The point when a 
lesion can be found through screening marks the beginning of the sojourn time (detectable 
6 
preclinical phase of the disease). Sojourn time is a combined function of the lesions and of the 
screening test. Lead time will also be affected by frequency of screening, depending on the 
distribution of the sojourn time. Both sojourn and lead time vary widely in a population and 
neither is directly observable for an individual unless the screening test is repeated at frequent 
intervals. Thus screening frequency has a direct bearing on the sojourn time that is variable 
within a population.
2,36
 
Cervical cancer screening uses cytological tests such as Pap smear and Human 
papillomavirus (HPV) deoxyribonucleic acid (DNA) testing as techniques to detect and prevent 
invasive cervical cancer. The Pap smear test is described briefly in the next section.  
2.1 The Papanicolaou test 
The Papanicolaou (Pap) test was introduced into routine clinical practice in the late 1940s.
37
 
This test is conventionally performed by sampling cervical cells and examining the cells for 
abnormalities. High quality samples enhance screening effectiveness. The best results for 
sampling cervical cells are obtained with a combination of extended tip spatula scraping of the 
ectocervix followed by a cytobrush to obtain an optimum endocervical sample. Both specimens 
are placed together on the same slide
 
 (i.e., “smear”) and the cells are examined under a 
microscope by a pathologist or a cytologist to look for abnormalities.
38,39 
The slide is classified 
as satisfactory or unsatisfactory. A Pap test slide is termed unsatisfactory if there are insufficient 
squamous epithelial cells (<10%), obscured by red blood cells or inflammatory exudates (white 
blood cells) or if contaminated
25
 (refer to Section 3.1.2 for more details).  
The purpose of the Pap test is to identify pre-cancerous changes called cervical 
intraepithelial neoplasia (CIN) or cervical dysplasia. The CIN 1, CIN 2, or CIN 3 would indicate 
respectively mild, moderate or severe cell changes. Results are reported to the Saskatchewan 
PPCC in the Bethesda categorization system.
40
 Abnormal results are subsequently reclassified 
into abnormal-low or abnormal-high categories (Saskatchewan PPCC; refer Section 3.1.2 for 
further details). A sample that has no abnormalities is reported as negative (i.e., normal). 
Examination using colposcopy and biopsy methods are used to follow-up on cases with a high 
grade of abnormality.
25,41
 
Two approaches used to operationalize screening are described in the following section.  
7 
2.2 Screening approaches 
There are two primary approaches to implement screening – opportunistic (spontaneous) 
and organized. The goal of opportunistic screening is to reduce disease incidence and mortality 
at an individual level. It typically includes any unsystematic screening activity and occurs when 
a test is offered to an individual without symptoms of the disease when they present to a health 
care practitioner for reasons unrelated to that disease.
42,43
 Cervical cancer screening in 
Saskatchewan from the early 1960s till the early 2000s when the PPCC was introduced was 
primarily opportunistic in nature.  
In contrast, the aim of organized screening is to reduce incidence and mortality of cervical 
cancer at a population level by systematically offering the test to all individuals in a defined 
target group on a population basis within the framework of agreed policy, protocols, quality 
management, monitoring and evaluation. Organized screening includes the following 
components: (1) clearly defined program objectives and expected health benefits; (2) an ability 
to identify individuals in the population (target group) that will benefit; (3) uses measures to 
facilitate high levels of participation such as invitation/reminder letters and health education; (4) 
provides adequate facilities for the following: managing referrals for abnormal results, a system 
to communicate normal results and follow-up for further diagnosis and treatment; (5) provides an 
organized quality control program for screening tests and their interpretation; (6) maintains data 
for regular program monitoring and evaluation.
 34,43
  
Although both organized and opportunistic screening strategies result in a reduction of 
cancer mortality and incidence
2
 the former offers the following advantages over the latter: (1) 
Organized screening maximizes population coverage compared to opportunistic screening.
43,44
 
By inviting and reminding women and through the use of longer screening intervals, the 
organized approach minimizes harms; (2) For the same reasons an organized screening approach 
is often more efficient and cost effective than the opportunistic approach;
45
 (3) As opportunistic 
screening is not centrally coordinated, continuous quality assurance and evaluation are not 
usually possible. As targets are typically not set and monitored, there are fewer options for 
population-based improvement. This also makes it difficult to interpret time trends since the 
extent and quality of opportunistic screening are often inconsistent; (4) Further opportunistic 
screening may result in differential access leading to higher coverage among younger healthier 
individuals who have a lower risk of developing the disease and lower coverage among older 
8 
harder-to-reach individuals and those of lower SES who are at a higher risk of developing the 
disease.
46,47
 By comparison, organized screening invites those not necessarily at highest risk but 
women in those age groups most likely to receive the greatest benefit from screening.
48
   
       Several Canadian reports have recommended that cervical cancer screening be implemented 
as an organized process.
18
 As discussed earlier, Saskatchewan also moved towards an organized 
screening approach due to gradually decreasing gains in incidence and mortality after a few 
decades of opportunistic screening. A number of other countries introduced nationwide 
organized cervical cancer screening programs using the Pap test much earlier than Canada. Many 
of these programs were of varied scope and targeted different age groups. The next section will 
discuss how screening effectiveness is measured before describing the features of these programs 
and their known effectiveness in reducing cervical cancer incidence and mortality.  
2.3 Measures of cervical cancer screening effectiveness 
          Screening effectiveness can be measured in a population in the following ways:  
(1) Survival; (2) Mortality; (3) Incidence. The suitability of each of these measures is discussed 
in the ensuing paragraphs.  
          Despite many studies using survival as a measure of screening effectiveness, it may not be 
an ideal measure as it is subject to three types of biases. First, screening is better at discovering 
indolent (slower progressing) cancers or long-lived cancers compared to cancers that rapidly 
progress.
49
 So the survival of people with screen-detected cancers is usually better than cases that 
were detected clinically (length time bias). Next, people who choose to participate in screening 
may differ from those who chose not to participate. For example, previous studies have shown 
that younger healthier individuals often self-select to attend screening compared to the elderly 
which may influence survival (volunteer bias).
46,47
 Finally, when cervical cancer is detected early 
through screening, survival time is often overestimated as the starting time point for survival gets 
shifted “backwards” (lead time bias).50 
 Randomized clinical trials (RCTs) that assess reductions in incidence and mortality are 
considered the most valid “gold standard” method to evaluate the relationship between incidence 
and mortality. Unlike colorectal (fecal occult blood test; FOBT) and breast cancer screening tests 
(mammography) that were implemented with RCT evidence, Pap tests were an accepted part of 
health care before RCTs were conducted. One randomized cluster trial was conducted in India.  
9 
This randomized trial reported that even a single lifetime screen with the HPV cervical cancer 
screening test and follow-up for eight years reduced advanced cervical cancer incidence by 0.47 
(95% CI: 0.32-0.69) and mortality by 0.52 (95% CI: 0.33-0.83) in comparison with a control 
group that received no Pap smear test.
51
 Paucity of randomized clinical trials mean that evidence 
for cervical cancer screening effectiveness comes from studying incidence and mortality trends 
and observational studies.  
     Trends in cancer mortality have been used as the primary measure for assessing 
screening effectiveness. As cervical cancer screening also discovers pre-cancerous lesions (e.g. 
squamous cancers) that can be treated to prevent invasive cancer it can be argued that changes in 
incidence of invasive cancer can also be used as a surrogate measure for screening effectiveness. 
However, this approach is not without its limitations. While examining time trends in incidence 
and mortality, it is often difficult to separate the effects of screening from improvements in 
treatment as well as cancer coding changes.  
The utility of incidence and mortality as measures of screening effectiveness lie in 
comparing incidence and mortality data before and after the implementation of screening 
programs, as discussed in the next section. As well, relevant observational studies pertaining to 
other programs are also described in the following sections.  
2.4 Review of screening programs in developed countries outside of Canada.  
         About 85% of cervical cancer cases occur outside North America and Europe primarily in 
developing countries where it accounts for 13% of all female cancers.
1,52
 In contrast, cervical 
cancer accounts for only 3.6% of female cancers in developed countries.
53
 Developing countries 
are disproportionately affected by cervical cancer compared to developed nations. Cervical 
cancer age-standardized incidence and mortality rates were 18 and 10 per 100,000 respectively in 
developing countries compared to 9 and 3 per 100,000 respectively in more developed 
countries.
54
  
This reduction in the cancer incidence and mortality burden in developed countries was 
realized in large part due to opportunistic and organized Pap smear testing implemented over 
several decades. Some examples of these screening programs and their experience in reducing 
the cervical cancer incidence and mortality burden are discussed here.  
In the United Kingdom, Pap smears have been used as a screening test for women over the 
age of 35 since the 1960s (on a five-year interval). During this period, health care providers 
10 
delivered the test inconsistently and a large number of women were provided repeat tests in 
intervals of less than five years with nearly 50% of the tests being provided to women younger 
than 35 years of age.
55
 Over the following 20 years, cervical screening failed to achieve 
sufficient coverage of women or follow-up of all women with abnormal results. Therefore the 
United Kingdom re-launched its National Cervical Screening Program in 1988 by establishing a 
national call and recall system covering women between 20 and 69 years. The screening interval 
was switched to three-years for 25-49 year old and remained at five-years for 50-64 year old 
clients. 
56,57,58,59,60,61
 An English study showed that the national call and recall system and 
incentive payments to general practitioners increased the coverage of target groups to around 
85%.
58
 This increased coverage of cervical cancer screening significantly affected the cervical 
cancer incidence and mortality rates. Cancer registration showed a broad increase in the 
detection of cervix in situ cases relative to the number of Pap tests. Cervical cancer incidence 
first increased when the Pap smear test was introduced, but incidence fell continuously 
throughout the 1990s. The cervical cancer incidence rate in 1995 was 35% lower than in the 
1980s for clients aged 30 to 74. Cervical cancer mortality fell steadily by 1.5% each year.  By 
1997, mortality rates per 100,000 population fell to 3.7, from 11.2 in 1950.
58,62,63  
In Finland, the cytology screening program started in the early 1960s and was designed to 
cover women aged 25-60 years old. The Pap smear test was offered by both public and private 
organizations. Every woman received a personal invitation to be screened at five-year intervals, 
generally from the age of 30.
64
 Two studies in Finland reported that organized cervical 
screening had reduced the cervical cancer incidence and mortality rates between 1962 and 1993. 
By the early 1990s, age-adjusted incidence and mortality rates decreased by about 80%. The 
nationwide screening program was shown to be the main reason for these results.
65,66   
In Norway, the Norwegian Cancer Society started a cytological mass screening program in 
the county of Ostfold in 1959. This screening program defined the target population as women 
aged 25-59 years old. The screening interval was two years between the first and second screens 
and three years between the second and third and between the third and fourth screens.
67,68
 All 
Nordic countries showed declining trends in incidence and mortality rates from 1986 to 1995. 
This reduction in both the incidence and mortality rates was largely attributed to the mass 
screening programs. The greatest reduction in incidence and mortality rates was found in 
Iceland (67% in incidence and 76% in mortality), an intermediate reduction in Sweden (55% 
11 
and 60% respectively), and the lowest reduction was observed in Norway (34% and 43% 
respectively).
69,70
  
Cervical cancer screening program policy generally differs across member states of the 
European Union. Some programs set only minimal guidelines for cervical screening. For 
example, nationwide cervical cancer screening in Luxembourg covers annual screening of 
women aged 15, with no upper bound limit on age. By contrast, both Ireland and Belgium target 
women between 25 and 64 years with a screening interval of three years. Still other countries 
screen a slightly different target population. As an example Estonia’s population-based 
screening program recommends that women start screening by 30 years of age till age 59, in 
intervals of five years.
 71,72
  
The National Cervical Cancer Screening Program in Australia was introduced in 1991. 
The program guidelines recommended a biennial screening cycle for sexually active women 
aged 18 to 70 years old. A study of this national screening program reported that it has been 
successful in reducing cervical cancer incidence and mortality rates.
73,74
  
After an opportunistic cervical smear screening in the 1950s in New Zealand, the country 
introduced its National Cervical Screening Program in 1990. Program guidelines recommended 
that all women between 20-69 years who have ever had sexual intercourse should be offered a 
Pap smear test at three-year intervals. A couple of studies demonstrated the impact of screening 
on incidence and mortality. The first study showed that age-standardized incidence and 
mortality rates of invasive cervical cancer had fallen by approximately 50% and 60%, 
respectively, from 1990 to 2004.
75
 A cohort study in New Zealand followed 1,063 women who 
were diagnosed with CIN3 (severe dysplasia or HSIL) between 1955 and 1976. A total of 143 of 
these patients were not offered treatment between 1965 and 1974. Thirty-years of follow-up 
data showed that, of the women who were not treated, 31.3% (95% CI: 22.7-42.3) developed 
invasive cervical or vaginal cancer. In the group that received appropriate treatment, only 0.7% 
(95% CI 0.3-1.9) went on to develop cancer.
11
 This study showed that although it was important 
to provide treatment to women with cervical abnormal cell, about 70% of these women who had 
CIN3 recovered without any treatment. The implication is that a screening program with a one-
year testing interval is likely to overestimate incidence and over treat women with abnormal 
results.
11
 
12 
Another study examined the impact of different screening intervals (two vs. three years) 
on cervical cancer incidence and mortality in Australia, New Zealand and England. The study 
concluded there was a significant fall of cervical cancer incidence and mortality in these 
countries after the introduction of an organized cervical cancer screening program. These 
findings did not support the biennial screening interval recommendation in Australia.
76
  
In the United States, cervical cancer incidence and mortality were reported to have 
declined since the 1950s, when the Pap smear test was introduced in the different states.
77,78
 In 
the early 1980s, the American Cancer Society Guidelines for the early detection of cervical 
cancer stated the following “…all women who are, or who have been, sexually active, or have 
reached age 18 should have an annual Pap test and pelvic examination. After a woman has had 
three or more consecutive satisfactory normal annual examination, the Pap test may be 
performed less frequently at the discretion of her physician.”79 By 1988, most American 
professional medical societies had accepted the guideline that the average woman need not 
undergo Pap smear screening annually. The US Centre for Disease Control and Prevention 
(CDC) eventually concluded that annual screening shows no clear advantage over less frequent 
screening, and may even lead to worse health outcomes due to a greater number of questionable 
abnormalities requiring investigation. The recommendation for the screening interval was 
changed to three years interval even though some physicians still prescribed the Pap smear in 
their own way, often with more frequent schedule than once every three years.
77,78,80
  
A landmark study by Sawaya and colleagues reported that the age-adjusted incidence rates 
of high-grade squamous intraepithelial lesion (HSIL) or worse were similar for women screened 
at one, two and three year interval (p=0.46). The incidence of smears interpreted as low-grade 
squamous intraepithelial lesion (LSIL) increased as time from the normal smear increased 
(P=0.01).
80
 The current United States Preventive Services Task Force (USPSTF) recommends 
“that women aged 21 to 65 should be screened with cytology (commonly known as a Pap smear) 
every 3 years. As an alternative, women aged 30 to 65 who want to be screened less frequently 
may choose the combination of cytology and human papillomavirus (HPV) testing every 5 years, 
which offers similar benefits to cytology only”.81 Screening also has the effect of detecting in 
situ cases earlier thereby increasing incidence while invasive cancer incidence decreased 
according to Wang’s study using data from 1991 to 1995.82  
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2.5 Review of cervical cancer screening programs in Canada 
2.5.1 Cervical Cancer Screening in Canada – British Columbia and the early years (1940s-
1960s) 
In Canada, diagnostic cervical cancer testing started in British Columbia (BC) in 1949. A 
group of doctors also found that the Pap smear technique was efficacious in detecting pre-clinical 
cancers of the cervix. This technique was gradually adopted across the province in the 1950s.
 
In the early 1960s, with the assistance of the Canadian Cancer Society, physicians started 
offering Pap tests to all women requesting oral contraceptives. Around this time, the cervical 
cancer screening program became provincial in scope with women receiving Pap tests on an 
annual interval.
83
 Cytological laboratories were required to process screening samples, 
necessitating the setup of these facilities. There were two surveys done by the Canadian Society 
of Cytology in the 1960s, which reported detailed information on cytological facilities in 
Canada.
84,85
 One of these surveys profiled laboratory objectives and the means of collecting and 
processing cytological specimens with a particular focus on the Cytology Program in BC.  
 As the value of the technique had already been established, an additional effort was 
initiated to evaluate whether administering annual Pap smears through systematic screening 
would appreciably reduce the incidence and mortality of invasive squamous cervical cancer 
among BC women over 20 years of age.
86,87
 To document such changes, cervical cancer rates in 
BC were monitored over a prolonged period. These studies demonstrated an 80% and 75% 
reduction in age-adjusted invasive cervical cancer incidence and mortality rates respectively over 
thirty years (1955-1985).
9,88,89,90,91
  
2.5.2 The Walton Report and the Canadian Task Force on Cervical Cancer Screening 
Programs (1970s-1990s) 
The British Columbian experience encouraged the federal government to develop further 
policies. During the Conference of Deputy Ministers of Health the urgency of developing 
comprehensive cervical cancer screening programs was recognized and it was recommended in 
the subsequent 1973 Walton Report that health authorities support the development of organized 
programs. At the first Task Force meeting in 1974, it was apparent that there was disagreement 
among the members regarding the value of cervical cancer screening programs. The Canadian 
Task Force on Cervical Cancer Screening Programs eventually produced and published its first 
report in 1976 in favor of organized screening.
18
 The conclusions and recommendations from the 
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Task Force were as follows: (1) initial Pap smears should be done for all women over the age of 
18 who have had sexual intercourse; (2) after two satisfactory Pap smear tests yearly without 
significant atypical finding,  further smears would be done at three-year intervals until the age of 
35, and thereafter at five-year intervals until the age of 60; (3) Screening would stop at age 60 if 
women had repeated satisfactory smears without significant atypia.
18
  
A follow-up survey in 1980 concluded that the recommendations of the Task Force had not 
been implemented at the provincial level. Of the twelve provinces and territories, ten showed no 
evidence that physicians had changed the frequency of Pap smear tests to match the 1976 clinical 
guidelines.
92
 The Walton Task Force reconvened in 1980 in response to this lack of 
implementation and out of concern that social sexual patterns were changing. This conference 
paid particular attention to questions related to screening frequency, laboratory quality control 
and adequate processes for follow-up. In addition, subsequent recommendations were made in 
1982 to deal with these issues and introduce standardization and quality improvement 
mechanisms.  This conference stressed in particular that improving the quality and sensitivity of 
screening and being able to reach women who had never had a Pap test would have a greater 
impact on mortality reduction than attempts to increase screening frequency. The report 
recommended that women who had sexual intercourse should generally be advised to attend 
screening annually between the ages of 18 and 35 years and thereafter every five years until 60 
years of age.
93,94
  
A National Workshop on Screening for Cancer of the Cervix was held in Ottawa in 1989 to 
review the 1982 recommendations and propose that cervical cancer screening programs be 
integrated into Canada’s health care system. The workshop participants grappled with the 
following problems with cervical cancer screening programs in Canada: (1) not all women at risk 
were being screened; (2) some physicians had not acquired the necessary skills to take 
satisfactory Pap smears; (3) some laboratories were too small to provide adequate experience for 
staff and adequate quality control; and (4) some women with cytological abnormalities detected 
were receiving inadequate follow-up and management. In addition, some women were being 
screened too frequently, resulting in an inappropriate use of resources.
95
  
This 1989 workshop identified and recommended that an organized screening program 
include the following components: (1) information systems; (2) quality improvement; and (3) 
recruitment.  
15 
Effective information systems are basic to the management of an organized cervical 
cancer screening program. The key guidelines were as follows: (1) all women 18 to 69 years of 
age who have had sexual intercourse should be encouraged to participate in cervical cytology 
screening; (2) those women who never had sexual intercourse or had a hysterectomy for benign 
conditions could be advised not to be undertake screening; (3) women over 69 years of age who 
previously had at least two satisfactory normal smears with negative result in the last nine years 
do not need to be screened; (4) two consecutive negative Pap smear tests and follow-up re-
screening should occur every three years up to age 69; and (5) an abnormal result was to be 
followed by Pap smear screening or colposcopy exam.
94,95
 
A number of provinces established computerized information systems around the time 
these recommendations came out. The most complex systems were those in British Columbia 
and Nova Scotia. In response to the 1989 recommendations, British Columbia’s cervical cancer 
screening program started a central laboratory and a colposcopy program to better manage pre-
invasive lesions.
93,94,95
 Nova Scotia introduced in 1991 an organized, accountable provincial 
cervical cancer screening program.
96
  
Quality improvement focused on the following aspects: (1) quality assurance in cytology, 
to ensure the quality of smears taken; (2) sample preparation and interpretation of results; (3) 
follow-up of women with normal and abnormal results; and (4) ensuring that the program as a 
whole was effective in recruiting and retaining women at risk.  
Recruitment turned out to be the hardest component to improve. Even in provinces with 
well-established programs, there is still much to do to reach the women. A comprehensive 
strategy for recruitment would include public and professional education and would be facilitated 
by information systems, particularly if these were linked to population-based programs that 
provide access to names and addresses of women at risk. There was concern that the idea of 
using administrative databases for recruitment in screening program may not be acceptable to 
women. However, Canadian research has shown that women are open to this approach.
97
 The 
initial invitation would be facilitated through information systems that would also ensure the 
timely recall of women for follow-up with the recall frequency depending on the nature of their 
previous screen result (normal/abnormal). 
As a follow-up to these activities, Health Canada convened another meeting to review the 
situation within the provinces with respect to the development of organized screening programs. 
16 
Participants at Interchange ‘95 requested a continued presence of the federal government in 
encouraging and facilitating information exchange at the provincial level.  
All provinces and territories were invited to join the Cervical Cancer Prevention Network 
(CCPN). The purpose of the CCPN is to continue to reduce the mortality and incidence from 
cervical cancer and its precursors in Canada by facilitating the implementation or enhancement 
of organized screening programs. The network continued previous efforts by continuing to 
concentrate on the following three components of an organized screening program: information 
systems, quality management and recruitment strategies.
98,99
  
Across Canada, age-standardized rates of invasive cervical cancer incidence declined by 58% 
from 1972-2006 (22.3 to 9.4 per 100,000) and mortality dropped by 83%, from 1952-2006 (13.2 
to 2.2 per 100,000). By age group, the greatest declines in both incidence and mortality were 
observed in women 45 years or older, with reductions as high as 74% for mortality and 69% for 
incidence.
100
 In Canada, there were two time periods of high screening density. In the beginning 
of the1960s, screening rates were linked to oral contraceptive prescriptions and pre/post natal 
care resulting in high screening rates among women younger than 35 years. In the early 1970s, 
cervical cancer screening was partially subsidized and ultimately was offered free of charge in 
1984 spurring an increase in uptake. By 1973, the screening rate was near 50%. The screening 
rate continued to increase and reached over 75% among women aged 18-64 years by 1997.
101
 
More recently the Canadian Task Force on Preventive Health Care (CTF-PHC) updated its 
cervical cancer screening guidelines based on new information about epidemiology and 
diagnosis of invasive cervical cancer after a thorough literature review. CTF-PHC concluded that 
an organized population-based cervical cancer screening program was the best choice. Updated 
guidelines differed by age group. It was strongly recommended to not routinely screen women 
aged 18-19, and weakly recommend routinely screening 20-24 year old women. Screening 
women younger than 25 years would potentially result in more harm than benefit. Screening 
women 30-69 year olds at three-year intervals was strongly recommended.
102
  
Today every province follows slightly different cervical cancer screening guidelines; not all 
programs follow the Task Force screening guidelines verbatim. Based on an environmental scan 
published in 2010, Table 2.1 provides a comparison of cervical cancer screening programs in 
Canada and their respective features.
103
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Table 2.1. Environmental scan of cervical cancer screening programs across Canada
103
 
Province Starting date Type of 
program 
Age group 
screened 
Screening interval Type of screening Data submission Invitation/Reminder/follow-up  
British Columbia 1949 Partially 
organized 
population- 
based (PB) 
20-69 Biennial Conventional Cytology electronically 
Histology and colposcopy 
manually entered 
Reminders and recall letters to 
physician 
Invitation program in initial stage 
Alberta 2000 Partially 
organized PB 
21-69 Every three years Conventional/Liquid 
based cytology 
Cytology electronic via 
encrypted test band 
Histology and colposcopy 
manually entered 
invitation letter 
Result letters reminder letters 
from health providers 
Saskatchewan 2003 Organized 
PB 
18-69 Annual and Triennial Conventional Cytology electronically 
Histology and colposcopy 
entered manually 
Invitation, recall, reminder, 
follow-up and result letters 
Follow-up with physicians using 
fax and phone call for 
abnormal/unsatisfactory 
Manitoba 2000 Partially 
organized PB 
18-69 Biennial Conventional Cytology submitted 
electronically 
Histology and colposcopy 
entered manually 
Letter to physician/women to 
follow-up with abnormal 
Referring women to colposcopy  
Invitation letters started in 2010 
Ontario 2000 
reorganized 
structure on 
April 1, 2009 
Partially 
organized 
Within 3-years 
of becoming 
sexually active 
to the age of 70 
Biennial 
 
Majority: Liquid 
Based cytology 
Some: conventional 
Cytology and histology 
electronically submitted 
through a Cytobase database 
N/A 
Quebec Currently no 
program  
N/A 18-69 Annually Conventional N/A N/A 
New Brunswick 2010 Spontaneous 
Organized 
PB will start 
20-69 Biennial Conventional 
Liquid Based 
cytology 
Cytology and histology 
electronically from labs to 
data repository 
No invitation letter 
Follow-up with physician only 
done in some health zones 
Nova Scotia 1991 Partially 
organized PB 
20-74 Biennial Conventional Cytology submitted 
electronically 
Histology and colposcopy 
entered manually 
Reminder to physician to follow 
up clients 
abnormal/unsatisfactory 
P.E.I 2001 Spontaneous 18-70 Biennial Conventional  N/A Notice to physician 
Colposcopy follow up 
abnormal/unsatisfactory 
Newfoundland 2003 Partially 
organized not 
use PB 
20-69 Annually Liquid based 
cytology 
Cytology and histology 
electronically, histology 
manually entered 
Physician invite women 
Northwest Territories No program N/A 20-70 Biennial Conventional/liquid 
based cytology 
N/A Health center invitation or 
reminder 
Yukon No program N/A 18-69 Biennial Conventional BC Cancer Agency BC Cancer Agency 
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Of note is that the Prevention Program for Cervical Cancer (PPCC) managed by the 
Saskatchewan Cancer Agency is one of the few programs that send invitation letters to all age-
eligible asymptomatic women regardless of where they live in the province. The next section 
reviews in some detail the history of cervical cancer screening in Saskatchewan.   
2.6 History of cervical cancer screening in Saskatchewan: past and present 
2.6.1 Screening in the opportunistic era 
In Saskatchewan, opportunistic cervical cancer screening began in the early 1960s. Health 
care providers simply followed the recommendations of the 1982 Canadian Task Force on 
Cervical Screening and provided the Pap test annually to all women who had started to have 
sexual intercourse or were between the ages of 18 to 35 years.
18,104
 Health care providers would 
also provide a Pap test any time a client made a request, or if oral contraceptives, premarital 
examinations, prenatal or postnatal care were requested. The reasons for giving women annual 
Pap tests are as follows: (1) By giving women repeated tests on an annual cycle, it mitigates the 
possibility of false negative test results; (2) By reminding and engaging with clients regularly on 
an annual basis physicians are able to encourage healthy behaviours among women; (3) When a 
woman requests contraceptives, it suggests that she has initiated sexual activity. A Pap test is 
needed to establish a baseline for future comparisons; (4) Health care providers prefer to give 
their patients a Pap test when receiving such a request as it might mean a change in sexual 
partners or may be related to multiple sexual partners.  
In 1962, there were seven laboratories that processed cytological tests in Saskatchewan and 
about 0.7% of women aged 25 or older took the test. By 1965, 7.1% of the same age group had 
completed Pap smears. A small number of cytological examinations were also performed in the 
laboratories of Saskatchewan’s larger hospitals. The availability of this service was gradually 
increased so that the personnel and facilities then available would not be overwhelmed. In 1965, 
the 32,300 Pap smears from approximately 16,150 females represented a 250% increase over the 
total recorded in 1964.
105
 By 1967, the percentage of women aged 25 or older who underwent 
screening reached 27%. The cytological examination process became more centralized, with the 
majority of cytological specimens examined in a laboratory at Regina Grey Nuns’ Hospital.106 In 
1971, about 41% of women aged 20 and over had Pap smears done. The age-standardized 
mortality rates of carcinoma of the uterus (that includes cervix cancer) dropped from 15.7 to 13.9, 
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then to 9.4 per 100,000 in 1950-52, 1960-62, and 1970-72 respectively in Saskatchewan for 
women aged 30 to 64 years old.
18 
 
As screening attendance and uptake increased rapidly in the early years, however, 
researchers expressed concern about several population behaviour patterns related to screening. 
The following are two behavioural screening patterns that were most noticeable: (1) The older 
the women were, the less likely they were to participate in screening regardless of their place of 
residence; (2) The number of women attending screening from rural areas relative to the rural 
population was dramatically lower than that of women living in urban areas. It became clear that 
the opportunistic screening needed to be more organized in order to further reduce the cervical 
cancer mortality rate overall as well as reduce the disparity between subgroups.
107
  
2.6.2 The beginning of an organized screening program 
In 1997, Saskatchewan Health Services Utilization and Research Commission (HSURC) 
published a report “A Comprehensive Approach to Cervical Cancer Screening.”  This working 
group examined cervical cancer screening through the following approach: (1) a medical 
literature review; (2) an analysis of physician billing data on screening coverage; (3) focus group 
interviews with Saskatchewan women; (4) focus groups with health care providers; (5) a report 
on current laboratory quality; and (6) a cost analysis for introducing an organized screening 
program in Saskatchewan. A plan for an organized cervical cancer screening program was also 
outlined.
107
 In 1998, a Task Force for Cervical Cancer Screening Committee was established, 
and in 1999, a final report on organized cervical cancer screening programs was released.
108
  
In 2001, the Saskatchewan Ministry of Health approved funding for the development of a 
screening program and the advisory committee for the PPCC was constituted in November 2001. 
In November 2002, the PPCC was advertised on the C95 Radio Marathon display and PPCC 
newsletters were mailed to all physicians in Saskatchewan. 
Chronologically, the milestones in PPCC’s progress during the first year of operation were 
as follows: in June 2003, finalized PPCC information, including recruitment and recall letters 
and advertisements in English, Cree and Dene were mailed to all the community health centers. 
In July 2003, all health clinics and health centers received packages of PPCC brochures for 
display. All radio stations and newspapers ran advertisements to promote the PPCC. The PPCC 
was gradually expanded in three phases. In August 2003, the PPCC started Phase I i.e., daily 
cytology imports from Regina Qu’Appelle Regional Health Authority (RQRHA) and Saskatoon 
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Regional Health Authority (SRHA). Invitation letters were generated at the rate of about 2000 
letters per day. In April 2004, the PPCC started Phase II starting with the import of historical and 
daily histological data. Follow-up of abnormal and unsatisfactory results were also recorded. All 
histology and colposcopy reports were manually entered. It should be noted that the manual 
entry of histology and colposcopy reports unfortunately, did not follow the same standards as the 
cytology file. Hardcopy (paper) reports were scanned and stored as images (PDF and JPG format) 
and not as synoptic electronic fields. This makes it challenging to analyze colposcopy results due 
to the limited availability of data unlike the cytology file. In June 2004, PPCC started Phase III 
by testing a web based application used by the labs. Primary care providers announced the 
transfer of non-normal Pap smear test result follow-up to the PPCC from cytology labs located in 
two health regions (RQRHA & SRHA). Cytology data were transferred daily to a centralized 
Integrated Screening Information System (ISIS) database. Appendix I describes the PPCC’s 
activities in detail in a tabular format.
109
  
The launch of the PPCC divides the history of cervical cancer screening in Saskatchewan 
into two parts. Before the PPCC started, women participated in cervical cancer screening 
opportunistically. Most physicians gave their female clients Pap smear tests annually if they 
knew their clients had begun to be sexually active. Women would have a Pap smear done when 
they requested oral contraceptives and pre and post-natal care from their family physicians. If 
physicians were aware of a woman changing sexual partners, they would recommend screening 
as well.  As a result, young women were more likely to be screened.
107
 Health care providers 
would also give women annual Pap smears if they had sexually transmitted infections because a 
cervix infection might be related to HPV infection caused due to multiple sexual partners.  
It should be noted that even though participation in screening was spontaneous at this stage, 
health care providers preferred to provide Pap smear tests annually once the client had completed 
an initial test, regardless of the original reason for testing. Providers seemed to be more 
concerned with the false negatives. A false negative occurs when the test result is negative but 
the client actually possesses the attribute which is being tested.
50
 Repeated tests generated large 
volumes of data that were difficult for the two labs (in RQRHA and SRHA) to manage. Since 
1994, the Cytology departments in RQRHA and SRHA contracted a private corporation, MDS 
intRlab, to provide information management services. Thus, data from the two regions were 
linked and a provincial database was created. The provincial database would ensure that these 
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two large health region labs would each have a complete set of clients cervical health 
information. 
2.6.3 Current Program 
The PPCC started in 2003 as an organized screening program, operated by the 
Saskatchewan Cancer Agency (SCA) and funded by the Saskatchewan Ministry of Health. 
Saskatchewan legislation allows the PPCC at SCA to access a provincial information system to 
receive all eligible women’s health insurance data when they turn 18 years old. The RQRHA and 
SRHA laboratories began discussions to replace the medical database system. Maintenance of a 
provincial database was deemed critical for the quality of the program. The ISIS database which 
was originally developed as the platform for the Screening Program for Breast Cancer was used 
to store and share PPCC data as well. The use of the MDS intLab system was stopped in the fall 
of 2004. Agreements between the two provincial labs and the SCA were expressly designed to 
enable the sharing of data essential to the PPCC’s function. Based on this agreement, the PPCC 
ISIS database receives cytology information from both labs daily.  
The Saskatchewan Cancer Agency plays a key role in the PPCC by maintaining a 
provincial information system to support recruitment, education, and evaluation. An advisory 
committee was established to support the PPCC’s functions and ongoing evaluation initiatives. 
The SCA is also involved in performance monitoring, research and evaluation of the PPCC.  
A key feature of the PPCC’s organized approach is the use of invitation letters that are sent 
to all women in Saskatchewan aged 18 to 69 years. It recommends cervical cancer screening to 
be initiated with the onset of sexual activity. As mentioned earlier, this is one of the most 
exhaustive outreach efforts among Canadian screening programs. The PPCC’s various 
components were based on the recommendations of the 1989 Canadian National Workshop on 
Screening of Cancer of the Cervix.
95,107,108
 The program uses mailing information from the 
Personal Health Registration System (PHRS) to send the invitation letters.  
The following are the four kinds of letters a woman could receive: (1) an initial invitation 
(Letter A); (2) result letter (Letter B) after the Pap test, which also informs the client when the 
next test should be (depending on the test result and how many tests they have attended to date); 
(3) a recall letter which is sent four weeks before the next test is due; and (4) a reminder letter if 
the woman fails to show up for the next test as recommended.  The following Table 2.2 describes 
these letters in further detail. 
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Table 2.2. Different kinds of letters sent to age-eligible women by the PPCC in Saskatchewan 
Letters Who gets the letter & 
Content of the letter 
When they are sent 
Invitation Letter 
(Letter A) 
1. All eligible women. 
2. Briefly introduce PPCC. 
3. Invite them to take a Pap smear test.  
4. Assure them that a result letter will be 
sent from the PPCC post-test. 
Letter A was first sent at the beginning 
August 2003.  The majority were sent in 
2003, 2004, and 2005. The volume dropped 
significantly as the program got older 
because most women in the target 
population had received at least one initial 
invitation letter. This letter is now sent 
mostly to new Saskatchewan residents and 
women who just turned 18 years of age.  
Result Letter 
(Letter B1) 
1. All women who had taken a test. 
2. Report the test results [about 95% are 
negative (normal), 3.5% abnormal low, 
<1% unsatisfactory, and <1% abnormal 
high]. 
3. Inform them when they need to test 
again [negative, 1 year later; abnormal 
low or unsatisfactory, within 3-6 
months; abnormal high, refer to 
colposcopy within 6 weeks]. 
The number of Letter B1 sent correlates 
highly with the number of Letter A.  
 
Regardless of a woman’s previous screening 
history, PPCC treats the first test after the 
invitation letter as if this was the woman’s 
first Pap smear test. 
 
Results Letter  
(Letter B2) 
1. All women who receive a second 
negative (normal) test result. 
2. They return to screen after a three-year 
interval. 
Letter volumes increase over time because 
most test results are negative (normal). In 
principle, for a letter first sent in 2005 when 
a woman who had taken a test in 2003 
would have gotten two negative test results.  
Recall Letter 
(Letter C) 
1. All women who are due for a test 
2. Sent 4 weeks before the due date 
3. Due date is personalized depending on 
the previous test result 
 
 
This letter’s volume correlates with letters 
B1 and B2 because it is only sent to women 
who have received a result letter but who 
have not taken the Pap test a month before 
the due date. 
Reminder letter 
(Letter D) 
1. All women who fail to take a test on 
schedule 
2. Sent 6 months after the due date has 
passed 
This letter’s volume correlates with Letter C 
because a certain proportion of women who 
receive Letter C fail to follow-up on 
schedule. This proportion increases slowly 
over time. 
 
In practice, letters A and B are the most common letters sent to women in PPCC’s age-
eligible target population and its participants respectively. Educational literature on cervical 
cancer and Pap tests are enclosed with each result letter. This material provides information on 
the Pap test, guidelines for the frequency of Pap testing, information on colposcopy and the 
process to be followed post-colposcopy, treatment for abnormal cells found (Appendix II) and 
includes an opt-out form.  
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Women are advised to have an annual Pap test if they have more than one sexual partner, 
even if they had two consecutive negative test results. Information is also provided to help clients 
understand what normal, abnormal and unsatisfactory test results mean. 
The PPCC staff does not contact clients directly by phone or mail regarding their abnormal 
results. If a woman receives an abnormal-low result but did not have a repeat test in six months, 
the PPCC staff will contact their physician or nurse practitioner by mail six months later. The 
PPCC staff will continue to contact the health care provider’s office by fax three months after the 
initial mailing and by phone three months after the facsimile if the PPCC ISIS database does not 
receive the woman’s Pap test result. Subsequently, the client will be considered to be “lost to 
follow-up.” The same method can be used to contact health care providers when women who had 
an abnormal-high result did not have a follow-up colposcopy exam performed. Unfortunately, 
the PPCC ISIS database does not have synoptic fields electronically stored for colposcopy and 
histology results. Therefore, these results are not analyzed in this study.  
It should be noted that a woman has the right to opt out of receiving any letters. There are 
two levels of opt-out available. Level 1 is a decline mail option. Women may choose to decline 
receiving any further letters from the PPCC. However the PPCC will continue to track the 
follow-up of abnormal and unsatisfactory results through health care providers. Level 2 is a data 
masking option. Women may choose to have their data masked so that it is not accessible for the 
purposes of the PPCC. Follow-up provided by the PPCC for abnormal and unsatisfactory Pap 
test results will no longer occur and follow-up becomes the sole responsibility of the healthcare 
provider. However, the PPCC will continue to receive and store information in a provincial 
database and cytology labs will have continued access to this information to perform proper 
analysis. After opting out, women can opt back in to the PPCC by using an opt-in form 
(Appendix III).  
Very few, about 0.32% of eligible women aged 18-69, actually chose to opt out. Among 
these, about 90% chose not to receive any letters from the PPCC, but their information is still 
collected. About 10% elect to neither receive letters nor have their information stored in the 
PPCC database. They prefer to contact their family physicians themselves. The PPCC will 
continue to receive their Pap smear results from their physicians and store them in the database.
25
 
These clients are not included in the analysis presented in this thesis.  
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In order to better grasp the comprehensiveness of the PPCC, a program logic model was 
drawn and is shown in Appendix IV. It describes the main objectives and components of the 
PPCC which are to provide education about cervical cancer and the benefits of screening, to 
inform women when they are due for a Pap test, to notify screened women of their Pap test 
results, and to work with care providers to ensure the appropriate follow-up of abnormal Pap test 
results. The logic model highlights the operational procedures, and activities, resources needed to 
run the program, outputs, performance indicators and both short-term and long-term outcomes. 
Based on the data available in an electronic fashion, the current study focused on the following 
three PPCC components: coverage of all age-eligible women, uptake of the Pap test and the 
appropriateness of cervical screening follow-up based on the 2003 clinical guidelines. The PPCC 
engages in a number of activities that serve to create awareness and educate the general 
population about the cervical cancer screening program. These educational initiatives highlight 
screening access and benefits. The PPCC, the SCA, the Association of Family Physicians, the 
College of Medicine and the Health regions are some of the resources that work together to 
reduce the cervical cancer burden in the province through screening. In terms of process, 
invitation letters are mailed to asymptomatic age-eligible clients. Clients then participate in 
screening by visiting their family physician, who promotes the program by educating clients on 
the appropriate use of the test. The PPCC aims to increase the number of women who initiate a 
Pap test and are appropriately screened, while decreasing over-screening and inconclusive results 
in the short-term. In the long-term however the PPCC aims to increase the detection rate for 
invasive and in situ cervical cancer thereby reducing the incidence and mortality of the disease. 
Measuring the success of the program is done through a number of indicators. The number of 
“initial tests” and client compliance in repeat testing are analyzed as well. The participation rate 
measures the number of women who received at least one test in a three-year period where as the 
retention rate measures the number of clients who return for repeat testing.  
The main source of data for this study was the ISIS database which links the clients’ 
personal information to their Pap test date and results. The two indicators (participation rate and 
retention rate) were analyzed. The short-term outcomes of the participation and retention rates 
will be discussed later. This dissertation did not focus on the long-term outcomes of the program.  
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2.6.4 The PPCC’s Clinical Guidelines (2003-2012) 
Appendix V provides the details of the 2003 PPCC guidelines. It should be noted that these 
guidelines changed in 2012. For this research the applicable guidelines were published in 2003. 
From 2003 to 2011, women who received a negative (i.e., normal) test were recommended to 
have another test a year later. If a woman had two consecutive negative Pap tests one year apart, 
then screening at three-year intervals was recommended. If the test results were abnormal-low or 
unsatisfactory, they were to test again within the three to six months interval. Clinical guidelines 
discouraged women from repeat testing within three months after an abnormal or unsatisfactory 
result. When the test result was an abnormal-high, they were referred to see a gynecologist or a 
specialist to have a colposcopy done within six weeks. 
2.6.5 The PPCC’s new clinical guidelines (2012-present) 
Since January 2012, the PPCC has adopted new clinical guidelines. It now asks eligible 
women to participate in Pap testing starting at 21 years of age. The screening interval was 
changed as well. The 2012 guidelines recommend that women be screened every two years until 
three consecutive normal results are obtained at which time the screening interval would default 
to every three years.
110
 As this dissertation only includes screens done in the period 2000-2011; 
therefore data collected under the regime of the new screening guidelines are not included.  
As mentioned previously, recruitment of clients is a particular focus for the PPCC because 
an uptake of 70% and over has been shown to be associated with substantial mortality reductions 
in trials.
2,111
 The use of invitation and recall letters coupled with an information system to contact 
the target population at risk is essential to attain this goal. The success of the PPCC in 
maximizing uptake is measured by both participation and retention measures as introduced 
briefly in the following section.  
2.7 The relationship between cervical cancer incidence, screening intervals, 
participation and retention 
The participation rate is one measure of access to the screening test.
112
 A significant decrease 
in the cervical cancer incidence and mortality depends on all eligible women having access to 
regular Pap tests as demonstrated by screening evidence and clinical guidelines.
113,114 
It is 
defined as the percentage of women with at least one Pap test within the defined screening period 
(refer to section 3.2 as well).  
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While regular participation in an organized screening program is essential to optimize the 
benefits of screening, it is also important to check if and how frequently clients come back to be 
screened after a negative (normal) Pap test. Thus retention rate is another indicator of a screening 
program’s success in reducing overall mortality associated with cervical cancer. Retention is 
defined as the percentage of eligible women re-screened within three years after a negative Pap 
test. The intervals for retaining women with a negative result can vary by geography or 
government and information on this measure is quite limited. In Australia, the percentage of 
women who had repeated their Pap test within the 21-month period following a normal Pap test 
was 26.2%.
115
 However, this measure reflects the proportion of women that were re-screened 
early (recommended screening interval in Australia is two years) versus their retention. The 
Canadian Partnership Against Cancer (CPAC) reports a more traditional retention rate of 80% 
i.e., 8 out of 10 clients aged 20-69 years came back within a 36-month period.
116
  
Participation (often termed uptake or coverage) and retention (sometimes called recall) are 
defined differently across the world, depending on medical guidelines and the context in which 
screening services are delivered. However, both measures and the screening interval are closely 
related to reductions in cervical cancer incidence. The International Agency for Research on 
Cancer (IARC) working group on evaluation of cancer screening programs combined a number 
of case-control studies to evaluate the reduction in incidence of invasive cervical cancer in 
women aged 35-64 with different frequencies of screening. They showed that screening once 
every 10 years reduced the incidence of invasive cancer by 64.1%, every five years by 83.6%, 
every three years by 90.8% every two years by 92.5% and every year by 93.5%. Of note is that 
the difference in incidence reduction between screening every year and every three years is only 
2.7%. The lifetime number of Pap tests ranged from 30 for annual screening to three when 
screened every 10 years. The conclusion was that the benefit of screening every year instead of 
every three years (a 2.7% incidence reduction) was low relative to the costs (twenty additional 
Pap tests per woman).
2,36
   
These results were further verified in a paper by Colditz et al.
117
 The authors used the IARC 
study results and participation rates from the American National Health Interview Survey (NHIS) 
to estimate the reduction in cervical cancer incidence by screening frequency among women in 
the United States. The NHIS states that 49% of American women are screened annually, 16% are 
screened every three years, and 35% of women who are not screened in the past three years 
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received a Pap test every 10 years. Using IARC estimates for reduction in cervical cancer 
incidence and applying them to the NHIS data resulted in an overall reduction of cancer 
incidence by 82.8%. If the 49% of American women who undergo annual screening were instead 
screened every three years, the lifetime number of tests for these women would drop from 45 to 
15, accompanied by an incidence reduction from 93.5% to 90.8%. On the other hand, if the 35% 
of the women who were screened every 10 years were screened instead every three years the 
lifetime number of tests for these women would increase from five to fifteen and the reduction in 
cervical cancer incidence would increase from 64% to 90.8%. The conclusion was that if women 
were screened less frequently (i.e., every three years) there would be a decrease in the number of 
lifetime tests to 15 and a reduction in cervical incidence to 90.8%.
117
 Increasing the screening 
frequency among unscreened clients and dropping the testing frequency in other groups is an 
effective strategy to reduce cancer incidence.  
It is recognized in the literature that these reductions in cervical cancer incidence from 
studies may not match what can be achieved operationally in practice. The IARC estimates that a 
well-organized cytological screening program for cervical cancer every three-five years in a 
target population between the ages of 35-64 years can reduce the incidence of cervical cancer by 
80% percent or more among the women screened.
2
 In Saskatchewan, prior to the introduction of 
the PPCC, women were screened annually. After the introduction of the PPCC, clients receive an 
annual Pap test for their first two tests, and then default to a three-year screening interval 
thereafter if two consecutive tests were normal (i.e., negative). The three-year screening interval 
is usually chosen as a tradeoff between reducing incidence and costs due to additional Pap tests 
and follow-up.  
A range of factors can influence the participation and retention rates in a screening program 
such as accessibility, health promotion, program characteristics and policies/guidelines regarding 
the recruitment and target age groups as well as screening intervals. Participation rates have been 
shown to be associated with age,
118
 geographical area
119
, specific ethnic cultural groups,
120,121,122
 
education level and household income.
123
 In order to further explore factors that may impact 
participation and retention in screening, a conceptual framework was adopted to guide the 
selection of variables as well as the analyses and interpretation, as described in the next section.  
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2.8 Conceptual Framework for cervical cancer screening program 
Popular in the field of cancer screening, the framework in Figure 2.1 is adapted from Zapka 
and Wagner’s Quality in the Continuum of Cancer Care (QCCC) model29,30 which in turn is 
based on the work of Anderson.
31,32
 and can be used to describe population cancer screening 
programs such as the PPCC in Saskatchewan as well as to guide the evaluation of such programs.  
This framework emphasizes that multiple levels of factors interact with each other to 
influence screening behaviour and ultimately determine the effectiveness of the programs like 
the PPCC. Some of the factors operate at the macro level while others are at the micro level. The 
following are the three levels for this framework: (A) The system level that includes public 
policy, regulation and clinical guidelines; (B) The provider level refers to the density (or 
availability) of health care professionals in geographic areas and the attitudes, training, 
knowledge and cultural sensitivity of physicians towards cancer screening; (C) The individual 
level encompasses women’s personal characteristics (e.g. attitudes, behaviour) and 
socioeconomic status. 
 
 
Figure 2.1 Levels and factors that impact the Prevention Program for Cervical Cancer 
 
Each of these factor groups are further described in detail in sections 2.8.1-2.8.3.  
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2.8.1 The System Level 
The Government of Saskatchewan started work on implementing an organized cervical 
screening program in the early 1990s. The HSURC in Saskatchewan reviewed the scientific 
literature and wrote a summary report in 1997.
107
 The SCA was asked to organize a cervical 
cancer screening advisory committee and develop the PPCC. At this highest level, the focus was 
on the public policies and regulations that included establishing guidelines for the screening 
program and mandating coverage by the government, insurance or other entitlement programs. 
Insurance coverage for the test aimed to reduce barriers to accessing service.
124,125
 In addition, 
legislation authorized the SCA to receive health information in connection with the PPCC 
database. These specific policies for the PPCC enabled the government health information 
system to use the information related to women’s identification such as names, health card 
number, birth date, and mailing address to reach out to the eligible women. One of the most 
important building blocks of an organized screening program is a population-based information 
system. Identification of age-eligible women (18-69 years) made it possible for the PPCC to send 
invitation letters, recall letters and reminder letters to Saskatchewan eligible women to encourage 
them to participate in a Pap smear testing. Moreover, this system allows the PPCC to send 
personalized letters to women that contains information appropriate to the specific individual. 
For example, the recommended time for the next screening is predicated on several factors, 
which include whether the woman has already taken a Pap smear test and the result of the last 
test. The woman’s healthcare provider might be informed if the test result indicates that she 
needs to follow-up with a physician. The PPCC database links the eligible women’s information 
with cytology result(s) from laboratories to further monitor the work done by the health care 
providers and their laboratories. Note that the PPCC will not send any invitation and result letters 
to those women who choose to opt-out of the program. The information collected allows the 
PPCC to compare its performance with other programs at a national and international 
level.
25,95,107
  
2.8.2 The Provider Level 
The factors at the healthcare provider level can significantly influence a woman’s 
likelihood of participating in cervical cancer screening. For example, the density of physicians in 
a given geographic area and the knowledge and attitudes of the physicians towards cancer 
screening are predictive of the participation of women living in that area.
126
 A Canadian study 
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using the Canadian Community Health Survey (CCHS) data found that women without regular 
doctors were significantly less likely (almost three times) to have ever taken a Pap test.
127
 It 
should be noted that the PPCC is a population-based cervical cancer screening program that 
notifies women when they are due for a Pap smear test and then sends them the results if they 
take the test. It also links the screening program with doctors and nurse practitioners to facilitate 
follow-up care if the test results are abnormal. The PPCC itself does not directly provide cervical 
cancer screening, nor does it conduct follow-up if the test results are abnormal. The success of 
the program depends on a network of health care providers and the way these providers work 
with their female clients to complete a Pap smear test and conduct appropriate follow-up 
examinations as needed.
128
  
In order to increase the availability of physicians or nurse practitioners in rural and remote 
areas financial incentives have been used. This has helped to increase the number of health care 
providers working in remote areas like northern Saskatchewan. Recognizing that many women 
in rural and remote areas do not have a family doctor or a nearby clinic to take the Pap smear test, 
the health care system has even organized “mobile medical care groups.” This increases access 
for women who are hard to reach and improves the chance that they will undergo a Pap smear 
test.  
2.8.2.1 Influence of physician attitudes and training on the quality of the Pap test taken 
 Physician attitude and training can affect the quality of the Pap test taken thereby having a 
direct impact on the health of screened clients. The attitude of health care providers influenced 
by their training, determines their expectations regarding cervical cancer screening.
129
 A study 
based on several US surveys reported that 31.3% of physicians recommended annual Pap smear 
test, 33.7% of them supported testing in two-year intervals, and 33.1% of them thought the test 
interval should be three or more years. Younger physicians are much more likely to favor a 
longer interval.  Forty-two percent of those physicians younger than 40 years recommended a 
three-year interval for Pap tests, while only 25% of physicians older than 60 years would 
recommend such a long interval.
130
 These physician attitudes can influence the behaviour of their 
clients and possibly affect the interval between screens.
131
    
A British study found that widespread training for general practitioners and nurses within a 
region encouraged the appropriate use of the Pap test. Indeed trained health care providers are 
more aware of recommended intervals for initial and repeat Pap testing and are able to prepare 
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proper slides following standard protocols after taking a smear. This training has been shown to 
lead to a significant drop in the number of unsatisfactory results from Pap tests.
132
 In addition, a 
study at the Johns Hopkins Hospital reported that early signs of squamous intraepithelial lesions 
can be difficult to recognize from poor quality specimens, and inadequate sampling may 
contribute to false negative diagnoses.
133
 Therefore, training on proper technique and timing for 
Pap smear collection can affect the result quality of a screening program and will eventually 
impact programmatic cost-effectiveness and clients’ experience.134,135 A systematic review 
recommended that health care providers receive training on educational outreach in order to 
reduce the embarrassment, distrust and anxiety faced by women who participate in cervical 
cancer screening. Moreover, health care centers should seek to reduce delays in scheduling visits, 
offer gender-matched providers when available and promote cultural competency in provider-
patient communication. All these factors could significantly impact the Pap smear screening 
rate.
136
 
2.8.2.2 Sex of the physician administering the Pap test 
The literature has shown that women are more likely to undergo Pap smear screening if 
they are seen by a female rather than a male physician. A number of factors that differ by 
physician gender could account for this aspect including differences in communication and the 
time spent by the physician with the client.  
Lurie et al demonstrated that that the odds of a female client having a Pap smear was 1.99 
times greater (95% CI: 1.72-2.30) with a female provider compared with a male physician after 
adjusting for client age and physician age and specialty. This effect was found to be more 
pronounced among internists and family practitioners.
137
 A follow-up study four years later, on 
154 male physicians, 190 female physicians and 794 clients evaluated the factors that influence 
screening with internists and general practitioners. The odds of being screened by a female 
primary care practitioner was 1.78 times more than if the physician was male (95% CI 1.69, 
1.87). Clients of male and female physicians had similar emotions, attitudes, and influences 
regarding Pap smear. Female physicians were more likely to engage in the following behaviours: 
(a) ask new patients about the components of prevention; (b) feel more personal responsibility to 
ensure that their clients received screening; (c) report more comfort in performing Pap tests; and 
(d) report that they spent more time per visit than male physicians. In multivariable analyses 
from the same study practice organization, patient preference for a family physician and 
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prevention orientation of female physicians accounted for up to 40% of screening rate 
differences between female and male physicians for Pap smears.
138
 
Several studies have documented differences in communication style between male and 
female physicians and client reports of doctor-patient communication. Although good 
communication was associated with higher screening rates, this effect was largely independent of 
physician gender.
139,140,141
 
A striking difference between physicians based on gender was that significantly more 
clients of female physicians indicated a preference for a female physician for some component of 
their care and reported they would be reluctant to undergo a Pap smear if only a male physician 
were available. Anecdotally, it is possible that male physicians themselves may be 
uncomfortable doing Pap smears for fear of sexual harassment suits or litigation (personal 
communication).  
Studying the effect of physician gender on the provision of health services is complicated 
by many possible confounding factors. For example, younger physicians may have higher 
screening rates as a result of a recent emphasis on preventative healthcare in medical training.  
In Saskatchewan, the gender of the family physician, internist or obstetrician-gynecologist 
providing the Pap test may have a bearing on participation rates. The Saskatchewan Ministry of 
Health estimates that between 2000 and 2011 about 31% of practicing physicians were female in 
the following specialties: internal medicine, obstetrics and gynecology and family medicine 
specialties across the province (personal communication). This comment is congruent with 
published estimates that put the proportion of female physicians practicing in Saskatchewan at 
32% (2007-2011), one of the lowest in Canada.
142
 As female clients prefer physicians of the 
same gender when Pap tests are performed, a lower proportion of female physicians in a region 
could serve as a disincentive to participation.  
2.8.3 The Individual Level 
  Many studies report on various factors at the individual level that are predictors of 
cervical cancer screening participation. It should be noted that the PPCC database only collects 
limited information about these individual factors from clients. Some of these factors i.e., age-at-
screen, geography, socioeconomic status, client attitudes to screening, other health behaviour and 
general mental health, marital status and client ethnicity are discussed in the following 
paragraphs.  
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2.8.3.1 Age-at-screen 
The 1996-97 National Population Health Survey (NPHS) in Canada reported that a high 
proportion of women aged 25-34 had at least one Pap test in their lifetime and a proportion of 
them also had time-appropriate tests i.e., within the three-year interval from their last test. In 
contrast, women aged 18-24 and 65+ were more likely to have never had a Pap test and were less 
likely to have received one in the past three years.
143
 Studies based on the Canadian Community 
Health Survey (CCHS; cycles 2000-2001, 2003, 2005, and 2008) also found that younger women 
18-29 years and older women in the 60-69 age group tend to have lower Pap test participation 
rates than women in the middle age range (30-59 years).
144
 A study from Manitoba, Canada 
found that older women were less likely to have a Pap smear done before they were diagnosed 
with invasive cervical cancer even though they had greater opportunity to be screened than 
younger women as they visit doctors much more frequently.
145
 Administrative data has also 
shown that among long-term immigrants (living in Canada ten years and more) and Canadian-
born residents, older women were less likely to have had a recent Pap test.
146
 A chart review 
study of First Nations women in British Columbia also demonstrated that older women were less 
likely to have been screened for cervical cancer despite being at higher risk of developing the 
disease.
147
 A population-based study in USA reported that women fifty years and older were 3.4 
times more likely to be non-compliant with annual cervical cancer screening than younger 
women
148
 although another study seems to find different results.
149
 Paskett et al also conclude 
that older age in general was associated with a lower compliance rate in follow-up after receiving 
an abnormal Pap smear test result.
150,151,152  
2.8.3.2 Geography  
The US Preventive Services Task Force (USPTF) and other studies have reported that 
women who live in rural locations are less likely to receive a Pap smear test than those living in 
urban settings.
 153,154
 Two studies from Health Canada and the Ontario Health Survey similarly 
concluded that Pap smear test participation rates were lower among women who lived in rural 
and isolated locations in comparison to those living in urban areas.
155,156
 In Manitoba, rural 
family physicians were less likely than urban family physicians to provide women with a Pap 
smear test.
145
 Pap test prevalence was higher in city of Winnipeg than in south-rural and remote 
northern areas.
157 
 Studies in Australia also found that women who live in rural areas and remote 
areas had a significantly lower Pap smear test rate than those living in metropolitan areas.
158,159
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Mexican studies reported that rural women were much less likely to have taken any smear tests 
and if they did take tests, they were less likely to have their Pap tests done according to clinical 
guidelines using a specific testing interval.  
There are consequences to not having Pap smear tests. Lower cervical cancer screening rates 
among women from rural areas are associated with a higher mortality rate when compared to 
women living in urban areas. This is predicated on client knowledge and education as well. 
Women living in urban areas may have a greater understanding of the purpose of Pap smear 
screening than women living in rural areas.
160,161
 
2.8.3.3 Socioeconomic status  
Socioeconomic status (SES) has been shown to influence screening participation.
162
 SES is 
a determinant of health inequality that can be measured quantitatively as income. A health 
inequality is defined as any difference in the distribution of health status or health determinants 
between different population groups. When these differences are associated with systematic 
unfair conditions or circumstances at the population health, they are termed inequities.
163
  
Income is often chosen as a measure of individual SES as it is one of the most powerful 
determinants of health inequity. Measuring SES involves dividing the population into groups; 
these groups can be based on individual measures or area-based (e.g. income quintiles). This 
summary measure of inequality can help determine the degree to which socioeconomic groups 
are related to health outcomes. While individual information is the most direct way of classifying 
individuals by socioeconomic status, individual income is rarely available from health 
administrative data and public databases. When individual data on SES is absent, area-level 
income quintiles can be used as a proxy for individual level information.
164
 Neighbourhood 
income quintiles are an example of an area-based socioeconomic measure that characterizes the 
socioeconomic profile of a geographic area rather than that of individuals. This involves 
matching individuals to a spatial geographic location using information on their place of 
residence such as postal codes.
165
 The use of neighbourhood income quintiles to measure health 
inequalities has been increasing, in part due to the growing recognition of area and contextual 
level influences on health. By measuring SES, area mapping of inequalities is possible which in 
turn can be used to provide information and context to decision-makers through the construction 
of indices.
165,166,167
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Education is another measure used as a proxy for SES.
168,169,170
 The Australian National 
Health Survey reported that women with a higher SES had higher rates of Pap smear testing than 
women with a lower SES. Women with at least a bachelor degree were twice as likely to have 
had a Pap test within the past three years as those without a bachelor degree.  Women with a 
gross annual income of less than $20,000 were less likely to have a Pap smear test within three 
years. Women in white collar occupations were more likely to have a Pap smear test within three 
years than those in blue collar occupations.
162
 Part of this study also used data from the Pap Test 
Registry showing lower Pap testing rates among clients from a lower SES background in 
comparison to those from the highest quintile using the area of residence.
162
 The NPHS
143
 and a 
case-control study
145
 in Manitoba, Canada found a similar trend.  
A population-based study in Missouri, USA also found that women with less than high 
school education were less likely to have cervical cancer screening than those with at least a high 
school diploma.
148
 Women below the poverty level were twice as likely to have never heard of a 
Pap smear test. This measure was adjusted by household size. Women below the poverty level 
were also less likely to have had a Pap smear in the past three years.
171
  
According to the 2010 Canadian System Performance Report,
144
 the likelihood of having 
been screened steadily increased with increasing income and education levels. Women in the 
lowest income quintile reported screening rates of 71% compared to 87% for women in the 
highest income quintile. Similarly, women with less than a secondary school education had a 
participation rate of 64% while post-secondary graduates had a participation rate of 83%.
144
 Even 
among the new immigrant population in Canada, the rate of never having taken a Pap test was 
associated with education level: 69% for those with primary school education, 64% for those 
with a secondary and 46% for those with post-secondary education.
172
  
2.8.3.4 Client attitudes towards screening 
Women with higher education are often more likely to adopt new attitudes, especially if 
they are knowledge-based or are from a different culture.
173,174 Women’s attitudes and beliefs 
affect the uptake of the Pap smear test.
175
 Women who did not perceive Pap smear test as an 
effective preventative measure were significantly less likely to take the test compared to those 
who considered the test effective. Moreover, women who anticipated pain and embarrassment 
associated with the test were less likely to take the test.
176
 The British Household Panel Survey 
found that the more the women understood the test, the more likely they would take the test. This 
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study controlled for the other possible confounders such as socioeconomic status, and found that 
women’s participation in health educational courses (which include cancer screening) 
significantly increased their likelihood of taking Pap smear tests.
177
  
A Mexican study also reported that participants who showed an inadequate knowledge 
about Pap smear tests were significantly less likely to have had a Pap smear test than the women 
who were more knowledgeable.
160
 Studies from various other countries and regions have reached 
the same conclusion: lack of knowledge about Pap smear test is associated with a lower 
probability of participating in cervical cancer screening.
136,178
  
2.8.3.5 Other health behaviours and general mental health 
Health behaviours that resulted in positive health were associated with participation where 
as negative health behaviours constituted barriers for women who were less likely to engage in 
Pap testing. The National Population Health Survey (NPHS) cycle in 1996-97 reported that 
Canadian women who engaged in positive preventative health behaviours, such as blood 
pressure checks and regular exercise, were much more likely to report to have ever had a Pap 
smear test.
143
 On the other hand, the National Health Interview Surveys (NHIS) also found that 
women who smoked were less likely to have Pap smear done compared with women who never 
smoked.
179
 The US 2005 Health Information National Trends Survey (HINTS) found smoking 
and obesity were negatively correlated with the rate of participating in Pap smear tests.
180
 These 
results were also confirmed by the large observational study in the U.S. called Women’s Health 
Initiative.
181
  In general, unhealthy lifestyle behaviours have been noted to have a negative 
correlation with Pap test.
180,182,183,184
   
Studies on general mental health of women have found consistent trends. Women who 
experienced psychological distress were less likely to follow cervical cancer screening 
guidelines.
180,185
 Depression is associated with a lower Pap test participation.
186,187
 Significantly 
lower rates of on-schedule Pap tests have also been observed in women with psychiatric and 
substance use disorders.
188
  
 
2.8.3.6 Marital status 
An Australian study linking survey data with administrative data concluded that single 
women or women without children were significantly less likely to take the Pap smear test than 
married women or women with a partner even when controlling for the other characteristics such 
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as age and socioeconomic status.
189
 Studies in the US and in Mexico also reported that women 
who are married or with partners were more likely to have had a Pap test than single or separated 
women.  Women with children were more likely to have a Pap smear test done.
190,191
 The CCHS 
survey reached a similar conclusion; never married, separated, or divorced women were twice as 
likely to report that they have never had a Pap test, compared to their peers who were married or 
living in common-law relationship.
192
 A study in Britain also supported the general finding on 
the positive correlation between marriage and participation in cervical cancer screening.
193
 As 
the PPCC does not collect marital status from screening clients, this variable was unfortunately 
not evaluated here.  
2.8.3.7 Ethnicity  
People from an ethnic group are characterized by distinctive social and cultural traditions, 
maintained within the group and have a sense of identification with the group. Members of an 
ethnic group have a distinctive way of life, shared experiences, and often a common genetic 
heritage.
50
 These features may be reflected in their health and disease experience and shape their 
attitudes and behaviours towards screening. The number of female immigrants to Saskatchewan 
more than tripled in 2006-2011 to 13,425 women when compared to the previous 5 year period 
(2001-2005; 4,050 women).
194
  
In 2011 alone, about 4,410 women immigrated to Saskatchewan. Approximately 2,924 of 
these women would be in the target age group for screening by the PPCC, constituting only 0.85% 
of the total age-eligible covered population in Saskatchewan.
195
 The top three countries from 
which immigration occurred were the Philippines, China and India.
196
 These countries are 
generally grouped in the Asian (e.g. Chinese) and South Asian (India) categories. The 1996-97 
NPHS in Canada reported that Asian women between 25 and 64 years were almost eleven times 
more likely to report to have never had a Pap smear test compared with Canadian-born 
women.
143
According to the Ontario Health Survey and the CCHS, south Asian women were 
twice as likely to report to have never had a Pap test as white women. The longer the stay in 
Canada, the greater the likelihood of them having had a Pap test.
156
 
These results are seen in other countries that have a large ethnic population. A recent 
American study reported that Asians were the least likely to report that they attended cervical 
cancer screening. Screening rates even varied within Asian subgroups. Women of Vietnamese, 
Chinese, and South Asian origin were in particular less likely to have had a Pap test.
197
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In an American study, the Pap smear screening rates in the past three years was 
significantly lower among non-English-speaking Chinese women (24%).
198
 In Canada, a study in 
British Columbia reported that Chinese women were less likely to have had a Pap test within the 
last two years due to language barriers and knowledge about the Pap test.
199
 Language is closely 
associated with ethnic identity and could be a barrier to screening participation. Immigrants are 
often preoccupied with stresses from unemployment, isolation, misplacement, communication 
issues, or discrimination. They may not view preventative health care activities such as cancer 
screening as a priority.
200
 
2.8.3.8 Aboriginal ancestry and screening 
It is well known that Aboriginal Persons (First Nations, Inuit, and Métis) are less likely to 
engage in cancer prevention activities. A lower Pap smear rate was associated with a higher 
mortality rate from cervical cancer among First Nation women.
201
 A study in British Columbia 
(BC), Canada, using the Cervical Cytology Screening Program registry to analyze Pap smear test, 
found that First Nation women participation rate for cervical cancer screening was much lower 
than those for women of other ethnicities.
119,202
 A similar conclusion was drawn from a 
Manitoban study where Aboriginal women had higher age-standardized incidence rates of in situ 
and invasive cervical cancer which was attributed to their lower screening rate.
157
 Results from 
other countries including the USA and Australia mirror identical trends in cervical cancer 
incidence and screening in the Aboriginal population.
158,203,204
 Interestingly, two recent 
Manitoban studies comparing cervical screening participation rates between Aboriginal and non-
Aboriginal people showed a higher Pap test participation rate among 20-24 year-old in the 
Aboriginal women but not in the other age groups.
205,206
  Further, cervical cancer incidence rates 
were still higher among Aboriginal women compared to their non-Aboriginal counterparts.
205,206
  
In Saskatchewan the two major Aboriginal people are First Nations and Métis. 
Saskatchewan’s population of self-identified Aboriginals increased gradually from 13.5% in 
2001 to 14.9% in 2006 to 15.6% of the total population in 2011, consistently the second highest 
in Canada after Manitoba. Aboriginals tend to be younger than the general population with a 
median age of 22.6 years (from 2011 NHS), significantly lower than the median age among non-
Aboriginals i.e., 40.9 years).
207,208 
    
Both cancer incidence and mortality are higher among Aboriginal Persons than in the 
general population. It is well documented that First Nations women experience much higher 
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incidence of cervical cancer in comparison to non-First Nations. From 1967-1986, invasive 
cervical cancer incidence rates among registered Indians in Saskatchewan was six times higher 
than that for the province.
209
  
Furthermore, among First Nations people, cervical cancer survival has been shown to be 
poorer in comparison to non-First Nations populations.
210 
Survival rates for First Nations and 
northerners have been shown to be equal to or poorer than non-First Nations. In Saskatchewan 
recent data are non-existent as Indian status is no longer collected. As an indication, in 1990, 
Irvine et al showed that five-year cervical cancer survival rates were 75% for First Nations, 66% 
for northerners and 76% for the province as a whole.
211
 Poorer survival may be attributable to 
less access to screening programs or other factors.
212
   
Focus groups have shown that cultural beliefs could play an important role in determining 
attendance at Pap test screening. Aboriginal women may feel more comfortable visiting 
traditional healers than engaging in screening procedures which they do not quite understand. A 
lack of understanding creates anxiety with some believing that the screening procedure itself 
could be a cause for cancer.
213
 Although ethnicity is an important factor in influencing screening 
participation, it is not recorded by the PPCC in Saskatchewan. Therefore, it cannot be explored 
in this analysis.  
2.9 Summary – conceptual framework and factors influencing screening 
participation 
Various factors can influence a woman’s decision to attend screening. The QCCC 
framework groups these factors into three levels as outlined previously.
30
 This framework has 
been adapted for the purposes of this study. This dissertation focuses on system and individual 
factors. System factors that will be explored in this thesis include: screening interval guidelines 
for repeat testing and the period in which the Pap test was provided. Individual factors include 
the following: age at screen, area-level socioeconomic status and the area of residence 
(urban/rural). While factors can operate at different levels, all of them can interact and/or 
influence each other.
29,30,31,32
 For example, the health care system sets policies which influence 
the attitudes and knowledge of the health care providers. This will in turn affect the effectiveness 
of a cancer screening program. It is important to consider all the factors in toto as there is a 
dynamic relationship between factors at the system and individual client levels that determines 
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participation (Figure 2.2).
214
 This study focuses on the following objectives drawn from the 
literature review as outlined in the next section.  
 
 
Figure 2.2 Adaptation of QCCC framework to current study 
2.10 Specific Objectives and Related Hypotheses  
 This study evaluates Saskatchewan cervical cancer screening participation and retention rates 
over time before and after the implementation of the organized PPCC program and the relative 
impact of socioeconomic status and urban/rural residential location (i.e., degree of rurality) on 
these rates. The following are three interrelated objectives that focus on different aspects of the 
PPCC:  
2.10.1 Objective 1 PPCC participation and retention rates, 2000-2011  
The first objective is to evaluate overall, age-specific, and age-standardized rates in 
Saskatchewan, from 2000 to 2011, before and after the introduction of the PPCC for (a) 
participation; and (b) retention.   
Two primary hypotheses to be tested are as follows: (a) The overall participation rate 
increased as a result of the PPCC’s efforts in actively recruiting women; (b) The retention rate 
among those who have undertaken screening also increased as a result of the PPCC’s efforts to 
remind women of their screening appointment through reminder letters. 
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2.10.2 Objective 2 Evaluate participation rates by urban/rural residential location and 
socioeconomic status 
The second objective has the following two components: (a) to compare and contrast 
overall, age-specific and age-standardized Pap test rates in urban areas compared to rural areas in 
Saskatchewan , 2000-2011; (b) to examine the relationship between socioeconomic status (SES) 
and Pap test participation rates for women living in urban areas from 2005 to 2007. 
 The two hypotheses being tested are as follows: (a) Pap test rates will be higher in urban 
than in rural areas; (b) Women who live in lower income (quintile) neighbourhoods will be less 
likely to attend Pap test screening compared to those who live in neighbourhoods with a higher 
income (quintile).  
2.10.3 Objective 3 Examining patterns of follow-up visits for women before and after the 
introduction of the PPCC  
The third objective is to examine follow-up visit patterns by clients (i.e., women), especially 
those who have had normal test results. In order to understand how women respond to the 2003 
clinical guidelines that recommend a reduced test frequency for women with normal test results, 
a detailed analysis of individual behavioural patterns was undertaken and presented.  
This objective was exploratory in nature and aims to examine the time course of follow-up 
tests by individual woman who have had one or two negative Pap tests. These analyses 
contributed to a greater understanding of the patterns of Pap test participation rates during the 
first decade of implementing the PPCC.   
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CHAPTER 3 
 METHODOLOGY 
This study uses administrative data to evaluate the PPCC in Saskatchewan. The available 
data sets were originally set up for administrative purposes, not for research purposes. Thus, 
much work was devoted to transform the data in order to use it for these analyses. The following 
briefly provides a general description of information available and the limits of the available data. 
3.1 Data sources  
 The following are the three major data sources used in this dissertation: (a) ISIS cytology 
database; (c) Saskatchewan Covered Population; and (d) Postal Code Conversion File plus 
(PCCF+). These data sources are described in further detail in the following paragraphs.  
3.1.1 ISIS cytology database 
   Client cytology information for this research was sourced from the ISIS database. ISIS is 
operated and maintained by the Early Detection and Information Technology departments at the 
SCA. This database is used by the PPCC to send invitation, recall, reminder, result and follow-up 
letters for subsequent diagnostic tests. Content in the database can be grouped into the following 
three categories: (a) client contact information and personal details; (b) Pap test and follow-up 
results and dates; (c) medical directive and proxy details the facilitate follow-up after the 
screening test.  
Client contact information and personal details: Clients are identified in the database 
using the unique Saskatchewan health services number (HSN) and a unique client identification 
number (i.e., “client ID”). The ISIS cytology database includes only those women with a valid 
Saskatchewan Health Service Number (HSN) and those who had at least one Pap smear test in 
Saskatchewan. This makes it challenging to compare the characteristics of women who have 
never participated in the program i.e., “never participants” to program participants. If a client is 
new to the province and does not have a HSN, she will not be in the data set. Thus clients who 
have recently migrated from other provinces will not be included in the database at least for the 
first three months post-migration. Further, students (or other transient workers) who come from 
other provinces but utilize Pap testing services in Saskatchewan were not included for the 
purposes of this analysis. It is expected that this number is fairly low and would not impact the 
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analysis in a substantial manner. The reverse situation is also possible, where clients hold 
Saskatchewan HSNs but receive Pap tests in other neighbouring provinces (Manitoba, Alberta) 
particularly in border towns. The estimated impact of this segment of the target population on the 
analysis is unknown.  
The ISIS database contains mailing addresses so that letters with specific content addressed 
to individual women can be sent to the right recipients. Other personal information contained in 
the database includes: date of birth, mailing address and residential postal codes and residence 
codes (i.e., rescodes). Residence codes are obtained from the Saskatchewan covered population 
book and are five digit numeric codes which uniquely identifies each city, town, village, rural 
municipality (RM) and First Nation in Saskatchewan.
215
 The first three digits indicate the rural 
municipality. Regional Health Authorities (RHA) or health regions often divide rural 
municipalities as these are differing administrative regions setup for different purposes. 
Therefore these rescodes are updated annually to incorporate area boundary changes for either 
the RHAs or RMs.  
Pap test and follow-up testing results and dates: Each Pap test is analyzed in one of two 
provincial laboratories in Saskatoon and Regina which generates a cytology result collected for 
each test. Each cytology number is assigned an accession number or cytology identification 
number (cytology ID). The test results dates that Pap smears were performed and cytological 
results processed are recorded in the database. The date that the lab receives the sample is 
recorded. If the cytological processing date is missing it is replaced by default by the date the lab 
received the sample. The database also serves to remind program staff to contact health care 
providers when women receive abnormal or unsatisfactory test results. 
Three categories of cytological results are reported i.e., negative result, positive result and 
unsatisfactory specimen. Further, positive results are grouped into abnormal-low and abnormal-
high categories. Abnormal results were grouped according to the 2001 Bethesda System which 
reports cervical or vaginal cytological diagnosis and Pap smear results.
216
 The PPCC data set 
does not have complete synoptic information in an electronic format on follow-up colposcopy, 
biopsies and histological results. Further, results where available electronically are not linked to 
specific Pap tests/Pap test dates.  
The abnormal-low category includes atypical glandular cells (AGC), atypical squamous 
cells of undetermined significance (ASC-US), atypical epithelial cells of undetermined 
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significance (ASE), atypical squamous cells in a background of atrophy which are present (ASA) 
and low-grade squamous intraepithelial lesions (LSIL). The abnormal-high category includes 
high-grade squamous intraepithelial lesions (HSIL), atypical squamous cells of undetermined 
significance (ASC-H), atypical glandular cells of endometrial origin are present (AGEM), 
Atypical squamous cells of undetermined significance are present - cannot exclude a high-grade 
squamous intraepithelial lesion (ASHG), abnormal glandular cells in situ (AIS), abnormal cells 
suspicious for adenocarcinoma (ACCAS), and abnormal cells representing a squamous 
intraepithelial lesion (ungraded, but probably high grade) (PC2). 
Unsatisfactory results refers to the following situations: (1) where 75% of the cells are 
obscured by blood, inflammatory exudates, thick areas, foreign contaminant, poor fixation; (2) 
squamous epithelial component covers<10% of slide; (3) broken slides; (4) unlabeled slides; (5) 
no slide received with requisition; (6) identifying information on the slide does not match 
requisition; and (7) requisition lacking patient name, provincial health number, and date of birth.  
Medical directive and proxy details for follow-up: As well, the database contains 
information on medical directives or proxy details to contact health care practitioners in the event 
of an abnormal test result.  
For this dissertation, Pap test and cytological data from 2000-2011 were used. While the 
ISIS database is primarily used to administer the PPCC it has also been employed for monitoring 
and research purposes. As with most administrative databases information on factors influencing 
client participation is limited, making it difficult to evaluate the association between risk factors 
and screening in a comprehensive manner. For example, the ISIS database does not 
systematically collect personal information such as marital status, ethnicity, educational 
attainment or household income. It also means the calculation of participation rates is based on 
the Saskatchewan covered population, which consists of aggregate data. The Saskatchewan 
Covered Population data source is described in the following section. 
3.1.2 Saskatchewan Covered Population 
The Saskatchewan Covered Population from 2000 to 2011 was sourced from the 
Saskatchewan Health Ministry and used as the denominator to compute the Pap smear 
participation rate.
217
 The provincial covered population is obtained using the Personal Health 
Registration System (PHRS) as the data source, based on eligibility for health insurance benefits 
in Saskatchewan. All Saskatchewan residents are included except: (a) members of the Canadian 
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Armed Forces, members of the Royal Canadian Mounted Police, and inmates of federal prisons, 
all of whom are covered by the federal government; and (b) people not yet meeting the residency 
requirement (coverage begins on the first day of the third calendar month following their move 
to Saskatchewan). Saskatchewan residents moving elsewhere remain eligible for coverage for the 
same period, and anyone whose coverage extends through June (i.e., who left the province April 
1
st
 or later) is included in the report. In case of death, people who had coverage any time in June 
are included.
218
 The Saskatchewan Covered Population file includes the following variables: sex, 
age, postal codes, residence code, health region and population counts. 
3.1.3 Postal Code Conversion File Plus 
The Postal Code Conversion File plus (PCCF+) is a complementary product to the PCCF. 
In this thesis, the PCCF+ was used to classify client residential postal codes into urban and rural 
areas. Further urban-area income quintiles were also assigned. PCCF+ is based on the latest 
PCCF and the postal code population weighted file created by the Geography Division of 
Statistics Canada. It is a digital file that allows the user to link Canada Post’s six character postal 
codes with Statistics Canada census geography units (e.g. dissemination areas (DA), census 
tracts (CT), census divisions and sub-divisions)
219,220 
while also providing the latitude and 
longitude for each postal code. The PCCF+ file is updated twice a year to add new postal codes, 
retire unused postal codes, and reinstate retired postal codes. Income quintiles were produced 
from the PCCF+ and assigned to the full range of the smallest geographical identifier down to 
DA and dissemination blocks based on the postal codes. PCCF+ version 5J is the most recent 
program, which was used for this analysis. The income quintile for this version has been updated 
based on the 2006 census data.
219,220
 PCCF+ has the following limitations: (a) ambiguity of rural 
postal codes; (b) inability to identify postal codes by institution; (c) difficulty in identifying 
postal codes linked to post office locations.
221
 
3.2 Description of measures and analysis for objective 1 
The first objective has two components: (1) to evaluate cervical screening participation rate 
(overall crude rate, age specific rates, and age-standardized rates) in the PPCC from 2000 to 
2011; (2) to examine the retention rate. 
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3.2.1 Pap smear participation rate calculation 
Definition: The Pap smear test participation rate is identified as the percentage of eligible 
women in the target population (i.e., 20-69 years) with at least one Pap test in a three-year period. 
This definition is based on the recommendations of the “Cervical Cancer Screening in Canada-
Monitoring Program Performance” report.222,223  
Analysis: The three-year rolling time frame is a standard way to calculate the participation 
rate in Canadian cancer literature. It has been used to evaluate the performance of cervical cancer 
screening programs in Canada.
222,223
 The first Pap smear test that occurs in a three-year time 
period is used. For example, contiguous three-year time periods are defined using the calendar 
year e.g. January 1, 2004 to December 31, 2006, which is followed by another three-year time 
period, January 1, 2005 to December 31, 2007. It is not possible to distinguish whether Pap 
smear tests were done for screening or diagnostic purposes the PPCC cytology database. 
Regardless of the purpose for the test, they are included in the numerator as “having had a test”. 
The women who have had a cervical cancer diagnosis and have had a hysterectomy would not be 
excluded from this analysis either. The client age at the time of screen is based on the first Pap 
test date in a three-year time period. Age-eligible women from the Saskatchewan covered 
population are selected from the middle year. For instance, if the three-year time period is from 
January 1, 2004 to December 31, 2006, the number of eligible women from the 2005 
Saskatchewan covered population are used as the denominator to calculate the Pap test 
participation rate.
222,223
 The Saskatchewan covered population does not change much from year 
to year. This analysis groups participants by ten-year age groups (20-29, 30-39, 40-49, 50-59, 
and 60-69).  
To examine if participation rate change over time and how the change was related to PPCC, 
two analyses were performed. First, the rate for each year was standardized and 95% confidence 
intervals were computed.
224
 Age-standardized (i.e age-adjusted) rates were calculated using the 
1991 Canadian population as standard.  
Second, spline analysis was used to test if there were two distinct trends for the Pap smear 
test participation rate using the year of starting the PPCC as the point where the trend changes its 
direction (i.e., the “knot”). Splines are defined here as piecewise polynomials of degree n with 
function values and first n-1 derivatives that agree at the points where they join. The abscissa or 
X-axis values of the join points are called knots.
225
 In using the spline knot analysis to describe 
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PPCC data, the knot was set to the time period 2002-2004. The reason is that 2003 was the year 
when the PPCC was launched, which is the middle year of the 2002-2004 time period.  
3.2.2 Retention Rate calculation 
The definition of retention rate is also based on the Canadian national 
recommendations.
222,223
 It is the percentage of eligible women re-screened within three years 
following a negative Pap test in a 12 month period. The denominator is the number of women 
with a negative Pap test in a 12-month period.  The numerator is the number of women who had 
a subsequent Pap test within three years of a negative result. 
Using the Pap test completion in the year 2000 as an example, the retention rate is 
calculated in the following manner. The denominator is the number of women who had a 
negative Pap test within a 12-month period. If the woman’s last Pap test was negative in 2000, 
this data point would be linked to the Pap smear cytology data from 2000 to 2003. Thus, clients 
with a negative result on their last Pap test are followed up for three years. The number of 
women who had a subsequent Pap test within 36 months is the numerator.  
The age-standardized retention rate was calculated for each follow-up period with 95% 
confidence intervals. Rates between time periods were then compared e.g. before and after the 
PPCC was launched. For the purpose of calculating retention rate, the women’s age were based 
on the date of the last negative test.  
The retention rate could only be calculated at the provincial level because the change of 
residence from region to region can be quite significant in a three-year period. These rates would 
not be accurate if they were calculated at the regional level.  
3.3 Description of methods and analysis for objective 2 
3.3.1 Definition of urban and rural areas 
Urban and rural areas were created using the data from PCCF+, which is based on the 
postal codes. Statistics Canada defines community size with 10,000 population or over as an 
urban area.
226,227 
Rural areas are those with less than 10,000 population. This definition is based 
on population thresholds that are determined nationally. However, in the context of a million 
residents in Saskatchewan what would normally be considered a rural place may in fact be an 
urban area in the Saskatchewan context. The definitions adopted here are to promote comparison 
to estimates made across Canada.  
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3.3.2 Calculation of participation rates between urban and rural areas 
The PPCC cytology data file includes information on postal codes. However, missing 
values required much work to fill the empty cells in the data file.  For example, the postal code 
can be found from the Canada Post website using the client mailing or home address. It should 
be acknowledged that this method is also not free of errors. The current home or mailing address 
may not be the same as the one when the Pap smear test occurred. Careful examination was 
carried out in order to minimize potential errors. 
PCCF+ is a collection of programs written in SAS that uses reference files from PCCF. The 
data linkage between the PPCC cytology file and PCCF+ can be done using the postal code. The 
prepared PPCC cytology file with client ID and postal code was inputted in the PCCF+ SAS 
program. The output of Health Output file (HLTOUT.GEO) and Problem Identified file (PRB) 
were checked. The HLTOUT file included the community size variable to define the urban and 
rural, income quintiles, and etc. The HLTOUT file was linked back to PPCC cytology file based 
on the client ID and postal code. The merged file named “CytoIncome” was used to calculate the 
number of eligible women, aged 20-69, who live in urban and rural areas and had Pap test done 
in the different time period such as 2000-2002, 2001-2003,…2009-2011.  
3.3.3 Calculation of socioeconomic status and participation rates in urban areas 
Neighbourhood income quintiles derived from Statistics Canada census data were used as a 
proxy measure for socioeconomic status (SES). Income quintiles were derived by using the 
following algorithm: (1) calculating the average (mean) household income of all residents; (2) 
rank them from poorest to wealthiest; (3) grouping them into five equally sized quintiles with 
each quintile comprising 20% of the population; (4) deriving income quintiles by aggregating 
household income to each dissemination area (DA).
219,220
 
It was not possible to apply the same income quintile calculation to rural areas using 
PCCF+ because of the high risk of misclassification.
228
 Therefore, only urban areas were 
included for this study where the income quintiles were linked to Pap smear participation rate. 
Also, the analysis was only restricted to clients who had at least one Pap test from 2005 to 2007. 
The reasons are as follows: (1) PCCF+ version 5J was based on the 2006 census information, 
and PCCF+ from 2011 census is not available yet. The income quintile from 2006 census was 
the most accurate measure; (2) there are only about 2% of postal codes missing for the cytology 
file 2005-2007. These missing postal codes were filled up by these women’s current postal codes 
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from their mailing address in 2012. The accuracy of postal codes in 2005-2007 was considered 
high, and it was much more accurate to generate income quintiles in urban areas; (3) the income 
quintiles from one period of time could be generalized to other time periods, as wealth 
distribution by residential area is not expected to change substantially.  
The files (CytoIncome and PopIncome) which were created from the analysis on Pap test in 
urban areas were used. The number of eligible women, aged 20-69, who had at least one Pap test 
in the urban areas was calculated based on the ten-year age group and income quintiles. The 
postal codes from the Saskatchewan covered population was based on the 2006 Saskatchewan 
health service card that would be the same as the postal codes from the 2006 mailing address. 
The new file that included the number of eligible women in the SK covered population in 2006 
was created in much the same way. These two new files allowed the calculation of number of 
women who attended a Pap smear test (numerator) and the number of SK covered population 
(denominator), by age and by income quintile.  
3.4 Description of methods and analysis for objective 3 
This objective aims to examine the pattern of follow-up Pap smear test in light of the new 
2003 guidelines’ recommendations for the follow-up time frame. The analysis examined the 
pattern by test results, when the first test was negative, when the two consecutive tests were 
negative and whenever the test was coded as abnormal-low or unsatisfactory. 
3.4.1 Distribution of Saskatchewan women who had their first Pap smear test 
As mentioned earlier, regardless of the number of Pap tests performed within a year (once 
annually or several tests per year), each woman could only be counted once in the participation 
rate in a three-year time period. The Pap test participation rate does not distinguish the woman 
who had three annual tests from those women who had only one follow-up test in three years. In 
other words, the individual pattern of these women who received Pap tests is unknown since the 
analysis only focused on women with at least one Pap test in a given time period.  
In order to examine the detailed pattern of follow-up behaviour, the data had to be 
reorganized. A data file was created with a single row representing each client (i.e., woman). 
Going from left to right, the row represents screening events occurring one after another as 
indicated by Pap test dates and separated by equal time intervals. When a client takes a test on a 
specified date, it is recorded as an “event”. Once the data were reorganized this way, then the 
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pattern of clients who received one or multiple Pap smear tests could be distinguished by number 
of tests and by time period. It allowed for a more detailed evaluation of individual behaviour 
pattern rather than simply calculating a general three-year participation rate.  
This reorganized data format has several limitations. It counts every woman who first 
entered PPCC system as having their first ever test, which is likely not true for many women.  
Many women would have been tested before and some of them might have had a test done the 
year before the PPCC was introduced. Also, the data set includes only the women aged 20-69. 
The first Pap smear test for many women probably took place at age 18. Thus, women who are 
recorded as having their first Pap smear test at age 20 in the current data set might very well have 
had tests done before they reached 20. Thus, the PPCC classification system has its own 
limitations. When PPCC started in 2003, it sent every woman an invitation letter as if she had 
never had a Pap smear test before. This analysis is limited by how the PPCC data were organized 
in the first few years of its operation.    
3.4.2 Women with a normal Pap smear test result that was followed-up within one-and-a-
half years 
If a woman’s first Pap smear test produces a negative result, then the question is whether or 
not she (and her physician) followed the guidelines for the next test. After one “first” normal 
result, it was expected that a second Pap test would occur a year later. To approximate real life 
situations, a grace period of six months was given in the analysis, using the same analytical 
strategy as the breast cancer screening program.
229,230 
There is no indication from the literature 
that the benefits of screening are lost if re-screening occurs up to six months after the 
recommended interval.
241
 Therefore the time frame under consideration would be a second Pap 
test within 18 months following the first negative result. The 2000-2009 trends were calculated 
in order to determine to what extent the PPCC influences the women’s behaviours regarding 
follow-up tests.  
This behavioural pattern was analyzed in two ways.  First, it was analyzed by grouping the 
“time to follow-up test” into the following discrete categories: (1) six months or less; (2) over six 
months and within one year; (3) over one year and within one-and-a-half years; (4) over one-
and-a-half years with no repeat test at all. The proportion of women who fell into each of these 
categories was calculated and was presented by time period from 2000 to 2011. 
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Second, the Kaplan-Meier survival analysis method (also called the product limit method) 
was used. This method was used to examine the follow-up pattern from first Pap smear test with 
negative result to the initiation of the second Pap smear test. More specifically, if a woman had a 
Pap test done after first negative result within one-and-a-half years, it was defined as an event. If 
women did not have any test done after one-and-a-half years, or did not come back at all, the 
case was censored. For example, if the first negative Pap test occurred in 2001 and within one- 
and-a-half years later, the second Pap test could not be later than June 30, 2003.  
In order to better ascertain when a client would most likely take another test after the first 
test, an event density function and hazard function were used to visualize the trends. The event 
density shows the probability of events in a defined unit of time. In this case, an event is when 
the woman takes the test. The hazard function shows the instantaneous probability of taking the 
test at any point of time given that women have not been re-tested up to that time. The density 
function and hazard function are visually more revealing than a survival curve, making it easier 
to pinpoint the time point when women are most likely to be re-tested.  
It should be noted that when the results of survival analysis are presented in the figures of 
the results section, more common terminology such as compliance is used instead of the 
mathematical concept of survival probability. The survival analysis is a mathematical description 
of how many women are in compliance with the 2003 Pap test clinical guidelines.   
In order to assess the effects of the PPCC on client’s follow-up behaviour, three time 
periods were chosen for comparison. The first one is 2001, which was before the PPCC was 
implemented. The second one is 2004, which was at the initial stage of the PPCC, and the last 
one is 2007. The last period represents the time period when the PPCC had been in operation for 
some time.     
3.4.3 Women with two normal Pap smear test results and followed-up for three-and-a-half 
years 
Based on the PPCC cervical screening guidelines, women who had two negative results 
within one and a half years of their previous test should only take their next test in three years. If 
the analysis allowed for a further grace period of six months, then any test that took place within 
the next three and a half years would be considered an “event.” The analytical methods used in 
this section were exactly the same as section 3.4.2.  
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3.4.4 Women with an abnormal-low or unsatisfactory test results.  
The methods used to analyze the follow-up data for women who had an abnormal-low or 
unsatisfactory test results were exactly the same as in section 3.4.2. The only difference is that 
the recommended follow-up time for both these categories is one year (including the grace 
period). 
3.4.5 Final model to analyze the pattern of follow-up with risk factors as covariates 
Cox’s regression model was used to test the pattern of follow-up Pap smear test by 
controlling for the effects of age, area of residence and household income. This modeling 
approach examined the patterns of follow-up for three test scenarios (when the test result was 
negative, abnormal-low, or unsatisfactory). This modeling approach also allowed for an 
assessment of the effect these risk factors would have under different scenarios. All three 
scenarios were tested because there are reasons to believe these risk factors may play a different 
role under different scenarios. For example, age may have a different effect based on whether the 
test result is normal or abnormal. In all cases, the assumption of proportionality was examined 
before the model was used. 
Risk factors can be found in the cytology database: (1) Time period of test: time period of 
the test is based on the date of the Pap test. The current cytology file includes all Pap smear tests 
performed from 2000 to 2011. There are three time periods that can be compared, the time before 
the PPCC, when PPCC just got started, and when PPCC was in operation for a number of years; 
(2) Age-at-screen: In the cytology file, client age-at-screen was defined as age calculated using 
the client’s birth date and Pap test date. The literature review suggests age is a risk factor for the 
Pap test. Therefore, it was analyzed, presented in the results section and its significance 
examined in the discussion section; (3) Client residential area:  A client’s residential area can be 
defined from their mailing address. Urban and rural areas are defined according to the Statistics 
Canada definition. The literature suggests that area of residence (geography) is a risk factor for 
attending Pap test screening;
155,156
 (4) Socioeconomic status (income quintile): Income quintiles 
are produced from PCCF+ as well. It is based on postal code and the population of dissemination 
areas (DAs). The average household income of all residences in a given DA was used for all 
clients in that area. As previously stated, income data are only available for clients living in 
urban areas.
228
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According to the literature, there are other factors which are known risk factors for not 
undertaking cervical cancer screening and not participating in this prevention practice. However, 
the PPCC administrative data set do not include more specific information unfortunately except 
those mentioned above.  
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CHAPTER 4 
 RESULTS 
In this chapter, study results are presented according to research objectives.  
4.1 Objective 1 
 The first objective has two components: a) to evaluate cervical screening participation rates in 
the PPCC from 2000 to 2011; b) to examine the retention rates. 
4.1.1 Participation rates before and after the PPCC was introduced  
Figure 4.1 presents the crude Pap test participation rates for women aged 20-69 in three-year 
rolling periods based on calendar year. The participation rate reached its peak in the 2002-2004 
period (64.7 %), which includes the first year of operation for the PPCC (2003), dropping 
slightly in 2003-2005. Since this period, participation has been on the decline, reaching its lowest 
level in the 2009-2011 period (60.9%).  
 
 
 
Figure 4.1 Crude Pap test participation rates in Saskatchewan, 2000-2002 to 2009-2011 
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Figure 4.2 displays the participation rate by age at screen. The effect of age on participation is 
clear and large in magnitude: the older the women were, the less likely they were to participate in 
cervical cancer screening. The trends over time for all the age groups however, were similar to 
that of the overall crude rate over twelve years. 
 
 
Figure 4.2 Age-specific Pap test participation rates, 2000-2002 to 2009-2011 
 
Figure 4.3 shows the age-standardized rates (adjusted to the 1991 Canadian population standard) 
and 95% confidence intervals. The age-standardized participation rate displays a similar trend to 
the crude rate. It was highest in 2002-2004 (66.2%) and then there was a slight decreasing trend 
over the years. Participation reached its lowest level in 2009-2011 (62.5%). The confidence 
intervals show that the screening rate in 2002-2004 was significantly higher than all other 
periods except for the period immediately after program inception i.e., 2003-2005. By 2009-2011, 
the screening rate had dropped to lower than the 2000-2002 period, before the PPCC started.  
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Figure 4.3 Age-standardized Pap test participation rates, 2000-2002 to 2009-2011 
                                
To summarize, there was an immediate increase in participation when the PPCC started. 
The participation rate appears to drop soon thereafter starting a consistent declining trend 
whether analyzed using crude or age-adjusted rates. Although the decline is small and gradual it 
appears to be real. By 2009-2011, the decrease was large enough that the participation rate was 
lower than before the PPCC started. By age group, participation was greater in younger age 
groups than for older clients.  
To formally test if there are indeed two different trends (i.e., an increase in participation 
due to the start of the PPCC and then a gradual decreasing period), particpation was analyzed 
using splines. This analysis used 2002-2004 as the knot because PPCC started in 2003 and the 
highest participation rate was expected in 2004. As shown in Figure 4.4, the results of the spline 
analysis indicated two statistically signficant trends: from 2000 to 2004, there was a signficant 
increasing trend (t=3.46, p <0.05) followed by a statistically significant decreasing trend since 
2004 (t=-3.91, p<0.01).   
If annual participation rate is used as the measure, instead of the usual three-year rolling 
rate shown throughout this thesis, the overall rate would be much lower than the three-year rate, 
but the trend would remain the same. Screen year 2004 had the highest annual participation rate. 
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When year 2004 was used as the knot, similar trends were found: a significantly increasing trend 
from 2000 to 2004 and signficantly decreasing trend following 2004 (data not shown here).  
 
 
Figure 4.4 A Spline Analysis on Two Trends with 2002-2004 as the Knot 
4.1.2 Retention rates  
Figure 4.5 shows crude retention rates for screens with a normal result that occurred 
between 2000 and 2008. With the follow-up period included, retention rates are measured over a 
twelve year period. The retention rate is defined as the proportion of eligible women re-screened 
within 36-months following a negative Pap test result that occurred in any twelve-month period. 
Retention is a conditional probability measure based on the initial negative test result. For 
example, even if a woman had multiple tests but her last result in the 2002 calendar year was 
negative, according to clinical guidelines she would come back for another test within the next 
36-months (i.e., up to 2005).  
The retention rate reached its zenith for women screened in 2002. Since the PPCC had its 
highest participation rate in 2002-2004, it is not surprising that the highest retention rate is in 
2002. This can be explained as follows: any woman who had a test in 2002 and then returned for 
testing any time in the 2003-2005 calendar year period is counted in the 2002 retention rate. The 
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retention rate decreased in 2003 and further decreased in 2004. It has remained relatively stable 
since then at around 74.0%.  
 
 
Figure 4.5 Crude retention rates, 2000 to 2008 
 
Figure 4.6 illustrates the age-specific retention rates over time. Similar to participation rate 
trends, retention rates decreased with increasing age. The youngest age group 20-29 years had 
the highest retention rate, a maximum of 81.5% in 2002. The retention rate for the middle age 
group 30-59 was lower, reaching 79.0% in 2002. The retention rate for the oldest age group 60-
69 was the lowest at 71.0% in 2002. The highest retention rate for this age group was 72.3% in 
the year of 2002.  All three age groups display a similar trend over time.  
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Figure 4.6 Age-specific Retention rate, 2000 to 2008 
 
Displayed in Figure 4.7 are the age-standardized retention rates between 2000 and 2008. 
Compared to 2004 – 2008 time periods, retention rates were higher between 2000 and 2003. It 
should be noted that any test taken within three years after a given test is considered part of the 
retention rate. Thus, an increase in screening participation in either 2003 or 2004 would increase 
retention in 2000 and 2001. In fact, the confidence intervals show that the retention rates for 
2000 and 2001 were significantly higher than the rate for 2004 and all subsequent years. The rate 
for 2002 was highest of all the screen years considered in this analysis.    
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Figure 4.7 Age-standardized retention rates (with 95% confidence interval), 2000 to 2008 
 
Overall, retention rates were higher than participation rates: the former was generally ten or 
more percentage points higher. This was to be expected given that the retention rate was 
calculated based on those who have participated in at least one test already. Moreover, the PPCC 
has increased the retention rate for those who were first screened before 2003. This could happen 
if more women came for a Pap test in 2003 and 2004 and if some of them had a test before the 
PPCC started. Therefore, retention was higher in the 2000, 2001 and 2002 screen years and fell 
when partcipation dropped after 2004. Since the retention rate is a measure of conditional 
probability, it is relatively more stable even if the participation rate drops slightly over time. The 
age-standardized retention rate has remained at about 74.0% since 2004.   
4.1.3 Summary of results for Objective 1  
Crude participation rates peaked in 2002-2004 at 64.7%. The PPCC was started in the 
same period. Since then participation has declined, reaching the lowest level (i.e., 60.9%) in the 
2009-2011 time period. Age-standardized rates displayed a similar trend with a peak in the 2002-
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2004 period (i.e., 66.2%) when they were adjusted by 1991 Canadian standard population. 
Further, younger women were more likely to participate than older women.  
Overall trends can mask age-specific participation patterns. Participation among 20-29 
year olds gradually reduced from 80.5% in 2000-2002 to 75.0% in 2009-2011. In contrast, 
participation among 30-39 year olds dropped from 68.0% to 66.4% while for 40-49 year olds 
participation was almost flat (from 61.0% to 60.6%). As the participating age increased the 
decrease in rate was attenuated. For older age groups there was slight increase in participation 
when comparing the 2000-2002 period to the 2009-2011 period. For 50-59 year olds 
participation went from 51.7% to 53.8%, while the 60-69 year age group experienced an increase 
in participation from 40.4% to 41.7% over the same twelve-year period.  
The spline analysis was performed for age-standardized participation rates with the 2002-
2004 period as the knot. Before this period, there is an upward trend in participation. After the 
knot period, the trend proceeds gradually downward.  
Retention rates generally followed the same pattern as participation rates. Crude retention 
rates in the 2000 screen year started off at 77.3% and increased thereafter till 2002 to 79.1%. 
From 2003-2008, there was a decreasing trend reaching 74.2% in 2008. Thus fewer women who 
had received a negative Pap test result returned for Pap tests within three years in successive 
screen periods post-2003. The age-standardized retention rate in 2002 was statistically 
significantly higher than in other years. Similar to participation rates, retention was higher for 
younger age groups than for older clients. From 2000 to 2008, retention displayed the following 
trend by age group: 20-29 years (80.5% to 79.5%), 30-59 years (76.8% to 73.4%), 60-69 years 
(71.1% to 64.1%). The drop in retention was most pronounced among older clients, particularly 
among those over 60 years of age, while the greatest percentages of returnees were from the 
youngest age group (20-29 years). Since 2003, initial participants in the 60-69 year group have 
contributed to the greatest decline in retention of all the three age groups. Retention trends were 
not as strong as participation rate trends, probably due to the fact that retention is conditional on 
initial participation with one normal test result.  
4.2 Objective 2 
The second objective has two components: (a) to compare and contrast overall, age-
specific and age-standardized Pap test rates in urban areas compared to rural areas in 
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Saskatchewan , 2000-2011; and (b) to examine the relationship between socioeconomic status 
(SES) and Pap test participation rates for women living in urban areas from 2005 to 2007. 
4.2.1 Participation Rates in Urban and Rural Areas 
Figure 4.8 presents the crude screening participation rates for rural and urban areas. 
Participation rates for rural areas were consistently 10%-20% lower than those for urban areas 
depending on the time period. For two successive periods, 2003-2005 and 2004-2006, urban area 
participation was 10% higher than in rural areas; in all other periods participation in urban areas 
exceeded that in rural areas by 20%. For both urban and rural areas periods of peak participation 
were followed by successive periods of gradual decline. Urban participation reached its highest 
level in 2002-2004 (68.3%) just after PPCC implementation, while uptake in rural areas peaked 
in the 2002-2004 and 2003-2005 periods (≈59%).  
 
Figure 4.8 Crude Pap test participation rates by urban and rural areas, 2000-2002 period to 2009-
2011 period 
 
Table 4.1 depicts age-specific participation rates over time and according to urban/rural status. 
Independent of time period and location, participation rates decreased as age increased.  Peak 
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among 20-29 year olds are provided here as sentinel examples. Participation ranged in rural areas 
from 74.7% among 20-29 year olds in the 2000-2002 period to 68.7% in the 2009-2011 period. 
By contrast, while urbanites showed higher participation than their rural counterparts (e.g. 20-29 
year age group 83.6% vs. 74.7% in 2000-2002 period), they also experienced a similar decline. 
Urban participation in the 20-29 year age group ranged from 83.6% (2000-2002) to 78.3% in 
(2009-2011). Following implementation of the PPCC in 2002-2004, the highest proportion of 
clients from urban areas (85.1%) in the 20-29 year age group participated in screening compared 
to 74.7% of the same age group in rural areas. The urban-rural gap in participation rates 
continued throughout the whole time period studied in this analysis. 
 Figure 4.9 shows the age-standardized participation rates (and 95% CI) for urban and 
rural areas. Similar to that observed with the crude rates, clients from rural areas were 
signficantly less likely than urban dwellers to participate in screening. As shown in Table 4.2, the 
higher participation rate of urban compared to rural dwellers remained quite consistent over time, 
with participation rate ratios ranging between 1.10 (2007-2009) and 1.16 (2009-2011). For both 
urban and rural clients,  participation peaked in 2002-2004 right after the PPCC was started at 
69.4% (95% CI: 68.8-69.6) and 61.3% (95% CI: 60.8-61.7), respectively (Figure 4.9). 
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Table 4.1. Pap smear screening rates (%) by age group (urban vs. rural), 2000-2002 to 2009-2011 
  Period 
Age group  2000-2002 2001-2003 2002-2004 2003-2005 2004-2006 2005-2007 2006-2008 2007-2009 2008-2010 2009-2011 
 (years) Rural Urban Rural Urban Rural Urban Rural Urban Rural Urban Rural Urban Rural Urban Rural Urban Rural Urban Rural Urban 
20-29 74.7 83.6 73.7 82.6 74.7 85.1 73.9 81.6 71.2 80.8 70.6 83.4 71.3 81.6 70.8 80.7 71.5 82.0 68.7 78.3 
30-39 62.9 70.9 63.4 73.3 65.6 72.5 65.3 72.3 64.9 71.4 64.9 72.6 63.9 70.9 62.2 70.4 62.2 71.5 60.3 69.5 
40-49 56.2 64.0 55.7 63.8 59.3 66.0 59.1 66.7 59.6 66.5 59.1 66.4 57.3 65.4 56.0 64.9 55.7 65.2 54.2 64.4 
50-59 47.3 55.0 47.1 54.7 50.6 57.8 50.9 57.5 50.9 57.3 51.0 57.2 50.7 57.1 49.9 57.7 50.2 57.7 49.2 56.8 
60-69 34.6 45.2 35.8 45.4 39.7 48.1 42.6 48.0 42.8 47.3 41.5 45.8 39.7 44.8 39.3 45.0 38.5 45.0 37.9 44.7 
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Figure 4.9 Pap smear age-standardized participation rates, 2000-2002 to 2009-2011 
 
Results of the spline analysis confirmed that there was a statistically significant positive 
participation trend up to 2004 and a significant negative trend following 2004 in both urban and 
rural areas (Figure 4.10).  
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Table 4.2. Age-standardized participation rate ratios (urban versus rural)  
(2000-2002 to 2009-2011) 
Period Rate Ratio (95% CI) 
2000-02 1.14 (1.10,1.11) 
2001-03 1.14 (1.09,1.11) 
2002-04 1.13 (1.09,1.11) 
2003-05 1.12 (1.09,1.11) 
2004-06 1.12 (1.09,1.11) 
2005-07 1.14 (1.09,1.11) 
2006-08 1.13 (1.09,1.11) 
2007-09 1.1 (1.09,1.11) 
2008-10 1.15 (1.19,1.21) 
2009-11 1.16 (1.19,1.21) 
 
 
  
 
Figure 4.10 Spline analysis for age-standardized participation rates by urban and rural areas, 
2000-2002 to 2009-2011  
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4.2.2 Participation Rates in Urban Areas by socioeconomic status 
Figure 4.11 shows the age-standardized participation rates by area-level income quintile 
(2005-2007) in urban Saskatchewan. A positive dose-response association was observed, with 
participation rates increasing as income quintile increased. Inspection of the confidence intervals 
indicated that participation rates in directly adjacent quintiles were statistically significantly 
different from each other.  
Table 4.3 compares the rate ratio for participation within each income quintile to the lowest 
income quintile (referent: Quintile 1; Q1). Here, the participation rate within Q2-Q5 was 
consistently higher compared to Q1 (range: 6-17%). All rate ratios were statistically significant. 
 
 
Figure 4.11 Age-standardized participation rates, by income quintile, 2005-2007 
 
Table 4.3. Age-standardized Participation Rate ratio with 95% CI of urban area income quintiles 
compared to Quintile 1 (Q1) as referent (2005-2007) 
Income Quintile Q1 Q2 Q3 Q4 Q5 
Rate Ratio (95% CI) Referent 1.06 (1.04 ,1.08) 1.09 (1.07 ,1.11) 1.13 (1.11 ,1.15) 1.17 (1.15 ,1.19) 
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4.2.3 Summary of results for objective 2  
Women living in urban areas had higher Pap smear participation rates than those residing 
in rural Saskatchewan – a pattern which remained consistent across age groups and screen 
periods. For both rural and urban women, participation peaked around the time that the PPCC 
was introduced and declined thereafter. In urban Saskatchewan in 2005-2007, participation in 
Pap smear screening decreased as area-level socioeconomic status decreased.  
4.3 Objective 3 
The third objective was to examine Pap smear test follow-up patterns over time in light of 
the 2003 clinical guidelines and recommendations.  
4.3.1 Distribution of follow-up Pap tests among Saskatchewan women who had their first 
Pap test 
In order to examine the pattern of follow-up tests among eligible women, the first test had 
to be determined for each woman. Table 4.4 shows the number of women who appear to have 
had their first Pap smear, as recorded in the PPCC database and the total number of women who 
are covered by the system. In the first year of available data, about half of the covered women 
(108,584 out of 304,220) entered into the system as having had their first Pap test. As expected, 
this number decreased over time. As more women entered the system, there were fewer women 
left who were not already in the system, despite the fact that the covered population grew slightly 
each year. The number of screens in 2001 (n=53,857) is approximately half of the number 
screened in 2000 (n=108,584). This percentage progressively reduced in every year of the 
PPCC’s operation.   
The data presented in Table 4.4 allows for estimation of the “ever-screened participation 
rate” without the rolling three-year period restriction. The last row shows the total number of 
women who have ever participated in a Pap test (n=323,240), by the year 2011. Of these women, 
8,686 are 60-69 years of age in 2000 and would likely be outside the target age range for 
screening by 2011. The total covered population is 341,294 by 2011. This means that 
approximately 92.2% of Saskatchewan women aged 20-69 have ever-participated in Pap test 
screening, after adjusting for those who become age-ineligible in 2011. This is an important 
estimation because the common participation rate calculation leads us to believe that about a 
third of all age-eligible Saskatchewan women have never participated in Pap test screening. 
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However this is not entirely accurate as the actual proportion of women who have never had the 
test seems to be much smaller suggesting that the never-participation rate is most likely less than 
10%. On the other hand the ever screening rate may still be an overestimation as the numerator 
includes women who may have moved out of SK. 
Between 2005 and 2011, the number of unique women getting their first Pap test stabilized 
to about 12,000. As the program was already three years old, this number better represents 
women who were getting their “true” first Pap test compared to earlier years of the PPCC’s 
operation. Since data is only available from the year 2000, it is likely that women tested in the 
first few years after the PPCC started had their first “true” Pap test prior to this date. After the 
PPCC was in operation for a number of years, the counts presented in Table 4.4 stabilized 
(around 2005-2006) and represent the actual number of women getting their first Pap test each 
year. In other words, in 2000, most of the women tested (approximately 95,000 women of 
108,000 participants) already had their first Pap test prior to that year. Further, the covered 
population change in this period averaged about 3,090 women a year in the 20-69 year age group, 
representing a 1% change each year for 12 years. Thus, the target population can be expected to 
be fairly “stable” in terms of new age-eligible entrants into the PPCC, further strengthening these 
results. 
Table 4.4. Number of women, 20-69 years of age, who appear in the PPCC system as having had 
their first Pap smear test and the covered female population, 2000 to 2011 
Year No# of women Change (%) Female pop 20-69 
2000 108,584  304,220 
2001 53,857 -50.4% 306,449 
2002 29,668 -44.9% 307,839 
2003 21,007 -29.2% 305,249 
2004 19,903 -5.3% 310,288 
2005 14,690 -26.2% 313,095 
2006 12,703 -13.5% 309,582 
2007 12,458 -1.9% 314,715 
2008 12,549 +0.7% 322,268 
2009 13,197 +4.9% 324,369 
2010 12,621 -4.4% 336,231 
2011 12,003 -4.9% 341,294 
Total 323,240  94.7% (ever screen) 
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4.3.2 Patterns of repeated Pap smear test following a negative test result 
Figure 4.12 demonstrates what happens when women who had normal test results returned 
for a second test. About 95% of the women had a normal result for their second test, about 3-5% 
of them had abnormal results and slightly less than 1% had unsatisfactory results. The proportion 
of abnormal results appears to be increasing over time. This can be attributed to the increasing 
proportion of younger women who are new to the screening program each year. Young women 
are much more likely to have an abnormal cervical test result. The age-standardized rate (based 
on the age distribution for screen year 2000) showed no significant difference for the rates of 
normal results from 2000 to 2009 (data not shown). 
 
 
Figure 4.12 Pap smear results distribution for the second test following the first negative test 
result within 1.5 years, 2000 to 2009. 
 
The proportion of women who had a second test done following the first negative result is 
shown in Figure 4.13. The PPCC adopted new clinical guidelines in 2003, which instructed 
women to have a repeat Pap smear done within one year following their first negative Pap smear 
test.  
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Figure 4.13 shows that in 2000, almost 50% of women did not have a repeat Pap smear 
done within the expected one and a half years. The proportion of clients that did not repeat a Pap 
test increased over time, to almost 70% in 2004. After 2004, this number declined. However, in 
2009, there were still about 65% of women who did not have a timely follow-up Pap smear.   
 
 
Figure 4.13 Timing of repeat Pap test following the first negative Pap result, 2000 to 2009. 
In order to better understand the follow-up pattern of women who had a negative test result 
on their first test, a Kaplan-Meier survival analysis was conducted in Figure 4.14. Survival 
analysis in this context shows the cumulative proportion of women who return for a Pap test over 
time. The advantage of showing this cumulative proportion curve is that it provides a visual 
representation of group behaviour over time without dividing them into discrete subgroups in 
Figure 4.13. In this analysis, if a woman who had one negative result had her second Pap smear 
done within 1.5 years; it would be defined as an “event” in the survival analysis, which means 
compliance with the 2003 clinical guidelines. If the woman did not have a second test done in a 
timely manner or the second test was delayed beyond 1.5 years, then she is censored (i.e., non-
compliant with the 2003 clinical guidelines).  
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Figure 4.14 divides the decade into three discrete time periods: 2001, 2004 and 2007. 
These periods were selected as follows: (1) the start date of the 2001 period included women 
who attended their “first” test before the PPCC began. Pap testing prior to 2003 was primarily 
opportunistic in nature, with an annual screening interval; (2) the start date of the 2004 period is 
the time frame when the greatest number of women participated in Pap smear tests, consistent 
with the PPCC’s proactive letters; and (3) the period starting in 2007 is the time frame after the 
PPCC had been implemented for four years. Thus, comparing these three periods could be 
informative. 
Repeat Pap testing patterns for clients who had their first negative test result in 2001, 2004 
and 2007 (testing periods) are profiled in Figure 4.14. 
The cumulative proportion of women returning at the six-month time point was similar 
among women who received normal test results in all three periods. At the twelve month point, 
the cumulative proportion for each of the time periods begin to diverge from each other, 
highlighting the difference between the three testing periods.    
These patterns suggest that about 40% of women tested after their first negative (i.e., 
normal) test result in 2001 return in eighteen months. This is the highest proportion of the three 
periods being compared. For women who received their first negative test result in 2004, 
approximately 30% return in eighteen months, the least of the three periods being compared. In 
contrast, of those women receiving a first negative in 2007, just over one-third complied with 
repeat testing guidelines. At the eighteen month time point, the slope of the three lines are 
roughly parallel, suggesting that testing patterns had normalized.  
Interestingly, when comparing the cumulative proportion of returning women initially 
tested in 2007 and 2001, there was little difference until the ten month point. This difference 
started around month ten and then increased by month twelve. Women initially tested in the 2007 
period were more likely to return for a second test in the recommended manner than those who 
attended their first test in the 2004 period just after the PPCC was first implemented.     
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Figure 4.14 Cumulative proportion of women returning for a repeat test following a negative 
initial test result 
 
Figure 4.15 displays an event density function which shows in one month units when the 
second screening event is more likely to take place. For all three periods, the second test most 
often occurs in month twelve following the first normal result. Overall, the degree to which 
women comply in each of the three periods is seen to be similar in both. Figure 4.14 and Figure 
4.15 i.e., a greater proportion of women returned if tested first in the 2001 period compared to 
the 2007 period, and a larger proportion returned if tested first in the 2007 period compared to 
the 2004 period. More women tested initially in the opportunistic testing era (2001 period) 
returned within twelve months compared with the other two time periods.   
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Figure 4.15 Event density function for women having a second test following a negative result 
 
To further delineate the difference in follow-up between these three time periods, the 
hazard functions for compliance curves are shown in Figure 4.16. The hazard rate in this case 
refers to the conditional probability of women taking the second test “tomorrow” given that they 
have not taken the test “until now”. In other words, these curves represent the probability that the 
women would take their second test in month N+1 given that they had not taken the test in 
month N. Thus, it measures the instantaneous probability of taking the second test given that it 
has not happened yet. The hazard function and event density function are mathematically related. 
The difference is that the former takes into account the total proportion of women who have not 
taken the test up to the time point in consideration. The conditional probability represented by 
the hazard function makes the change in any given point of time even more visually apparent. 
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Figure 4.16 Hazard function showing the conditional probability of taking a test given  
that women have not been compliant 
 
The hazard function shown in Figure 4.16 makes the difference between the three periods 
visually apparent. Also, time points at which women were most likely to take action and the time 
points at which differences begin to emerge are clarified. Comparing the curves for the 2001 and 
2004 periods, women included in the former were more likely to take their second test than those 
women in the latter period in almost all of the eighteen months following the first test. The 
difference becomes more noticeable after month nine and it is most prominent in month twelve.   
Figure 4.16 also shows that women tested in the third period (starting in 2007) were more 
likely to repeat the test compared to women in the second period (starting in 2004) in almost all 
months, starting in month six. Although the difference between these periods is less pronounced 
in comparison to the difference between curves for the 2001 period and the 2004 period, the 
pattern remains consistent.   
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4.3.3 Patterns of Pap smear test following two consecutive negative test results 
Figure 4.17 analyzes data for women who had taken two tests within the 1.5 year interval 
with both results testing negative. The analysis here relates to when they would take a third test. 
The timing of return testing is grouped into Four intervals: (1) one year or less; (2) more than one 
year and two years or less and; (3) more than two years and three and half years or less; and (4) 
more than three and half years or no return test. The 2003 clinical guidelines recommend these 
women come for another test three years later. 
Similar to the results presented in Figure 4.17 shows that the proportion of women who did 
not follow-up with another Pap test within the suggested time frame peaked for those who took 
their first test in the 2004 period. It is important to note, however, that most of these women did 
take another test within the ensuing three and a half year period. Even for those who took their 
first test in 2004, about 75% took the third test within the three and a half year period suggested 
by the guidelines.    
For those who did have their third Pap smear tests, most of them had the Pap smear done 
either within one year or between one and two years. In other words, even though they had two 
consecutive tests with negative results, these women appeared to have been compliant with the 
annual Pap smear schedule guidelines during the opportunistic era of screening before the PPCC 
began. 
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Figure 4.17 Next Pap test following two negative test results per year 
 
Figure 4.18 show the results of a “compliance function” analysis to describe the trends by 
dividing the decade into three time periods. Women who had two consecutive negative test 
results during 2001 and 2004 had very similar and low rates of taking their third test within one 
year (less than 30%); however, differences by time period began to emerge around month twelve. 
After month 25, the 2001 and 2004 curves appear almost parallel. 
The curve for the 2007 period is positioned between the 2001 and 2004 curves. There was a 
small difference between the 2004 period and the 2007 period curves in the first 12 months after 
the last test, although women in the 2007 period seem to have a slightly higher rate of taking 
their third test within the first 12 months. The difference between these two curves around month 
twelve is more clearly seen, and the difference appears to continue until the month twenty-five, 
after which the two curves appear almost parallel. 
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Figure 4.18 Cumulative proportion of returning test following two negative test results by time 
 
Figure 4.19 presents the event density functions for the three time periods. It shows more 
clearly that women tested in 2001 were more likely than women tested in 2004 to take their third 
test around month twelve. The difference between the 2001 and 2004 time periods continued to 
narrow until just before month twenty when the lines become parallel.   
 Figure 4.19 also shows that the probability of women taking their third test between  
months five and ten was slightly higher  in the 2007 period compared to the 2004 period at 
month twelve, the probability of having had a third test remains elevated in the 2007 period 
compared to 2004 – a pattern which continues until approximately month twenty-five. After 
month twenty-five, the curves for event density essentially overlap, which translates into two 
parallel lines as shown in Figure 4.18.    
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Figure 4.19 Event density function for returning test following two negative results 
 
Evident in Figure 4.19 is that, among women who did take a test following their two 
negative results, month twelve was the most likely time in which they returned for testing. This 
was true for all three periods examined. These results suggest that contrary to 2003 clinical 
guidelines, testing continued to follow old practice patterns prevalent in the opportunistic testing 
era (pre-2003). Had women experienced testing based on the 2003 guidelines, the most prevalent 
returning month would be either month 24 or month 36, depending on how they interpreted the 
term “third year” in the letters they received. However, the third test after two consecutive 
normal (negative) tests should definitely not occur in month twelve based on 2003 guidelines. 
The event density function also shows that after month twenty-five, the likelihood of any action 
taken in a given month is similar for all three time periods. This may explain why the three 
curves appear almost parallel after month twenty-five in Figure 4.18. The risk of return 
behaviour in twelve months reduced after the PPCC began in 2003.  
Figure 4.20 shows the conditional probability of taking a test given non-compliance by 
time period. Similar to the density function results, these curves show that women were most 
likely to take their follow-up test around twelve months after previous tests. This is true for all 
three time periods (2001, 2004 and 2007).   
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The hazard function, however, shows a subtle difference between the 2001 and 2004 
periods. Because there were many more women who followed-up with Pap tests in month twelve 
during the 2001 period than in the 2004 period, there were a smaller proportion of women in 
2001 who had not taken the test by month twelve. As a result, the hazard rate is higher for those 
women in period 2001 than those in period 2004. In fact, the difference between these two time 
periods is consistent from month twelve through month forty, even though the largest difference 
is in month twelve. 
 
 
Figure 4.20 Hazard function showing the conditional probability of taking a test given they have 
not been compliant 
 
To summarize, most women did not have follow-up with a second annual test when they 
had a first negative test result. If they did take the second test, it was most likely that they would 
do so in month twelve. If they did take a second test and received another negative test result, 
then they should, according to the 2003 PPCC guidelines, be retested in thirty-six months. 
However, this is not what happened. If these women did take another test, many of them would 
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take it in month twelve instead of recommended month thirty-six. In other words, it seems a 
subgroup of women took Pap smear tests annually even though they receive a negative test result 
in every test. The remaining women who had two consecutive negative (normal) tests would take 
their  third test at various times, but still closer to month twelve  rather than to month thirty-six.   
Compared to the 2001 period, women  in the 2004 and 2007 periods (after the PPCC started) 
were less likely to return for a screen in the first twelve months following two previous negative 
results.   
4.3.4 Repeated Pap smear test patterns following an abnormal-low result 
Figure 4.21 displays the follow-up test patterns of women receiving an abnormal-low result 
on their first test over time. Over fifty percent of these women obtained a normal result on their 
second test, forty percent received an abnormal-low result and approximately six percent 
received abnormal-high grade results. These patterns remained consistent over time. Therefore, it 
is important for these women following the 2003 clinical guidelines to have another Pap smear 
done within six months. 
 
Figure 4.21 Second test result following a first abnormal-low result, 2000-2010 
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Figure 4.22 Timing of follow-up test after an initial abnormal-low result 
 
Figure 4.22 shows the timing of the follow-up test after an initial abnormal-low result. 
Between 75% and 80% of women with an abnormal-low result had a repeat Pap smear done 
within one year. Overall it seems that both physicians and clients were following the 2003 
clinical guidelines for follow-up after an abnormal-low test result. After the PPCC started the 
proportion of women who returned in three months or less dropped by half (from 20% in 2003 to 
10% in 2010) signaling greater compliance with the 2003 clinical guidelines. 
           Figure 4.23 and Figure 4.24 present the results using a “compliance analysis”. Figure 4.23 
shows that women who had their first test with an abnormal-low result in the 2001 period were 
more likely to have a repeat Pap smear done within one year when compared to the other two 
groups which had their first Pap smear done after the PPCC began (in 2003). For those who had 
their first test in the 2004 and 2007 time periods, 75% returned at month twelve. This is different 
from the testing pattern discussed in the previous section, when the first test result was negative. 
In that case, the 2007 period had a slightly higher follow-up rate than the 2004 period.  
Figure 4.24 presents the event density probability, showing that month six is indeed the 
peak time for participants taking their second test in all three time periods. However, those who 
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took their first test in the 2001 period, compared to clients in the other two periods, had a higher 
probability of taking the test between six and eight months.   
Figure 4.24 also shows little difference overall between women who took their first test in 
the 2004 period and those in the 2007 period.  However, there is some variation (in opposing 
directions) in months three and nine.  
Figure 4.25 shows the hazard function for the three periods. Similar to the density function 
in the previous figure,  the hazard function shows that the 2001 period is very different from the 
other two periods. The biggest difference is in month six to eight: women in the 2001 period 
were much more likely to be retested after an abnormal-low test result. 
 
 
Figure 4.23 Cumulative proportion of returning test following an abnormal-low result 
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Figure 4.24 Event density function for returning test following an abnormal-low result 
 
 
Figure 4.25 Hazard function showing the conditional probability of taking a test following an 
abnormal-low result 
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There was a consistent difference between women tested in the 2001 period compared to 
those tested in periods 2004 and 2007.  
 Figure 4.24 and Figure 4.25 show similar trends. The likelihood of repeat testing within 
twelve months following an initial abnormal-low test result in the 2004 and 2007 periods (i.e., 
after the PPCC started) was consistently higher than for the 2001 period (i.e during the 
opportunistic testing era). Most women had another test after an initial abnormal-low test result; 
only about 25% of clients were non-compliant. Moreover, most clients had a follow-up test done 
between month six and month eight (peaks in Figure 4.24 and Figure 4.25) in accordance with 
2003 PPCC clinical guidelines. The probability of returning for a test after initial abnormal-low 
results in the 2001 period was slightly higher (0.30) than in the 2004 and 2007 periods (similar at 
0.20).  
4.3.5 Trend of repeated Pap smear test following an unsatisfactory result 
Before examining behavioural patterns, it is useful to look at the distribution of the second 
Pap smear test results following the first unsatisfactory test. Figure 4.26 shows that over 91% of 
clients tested normal, about 4% tested unsatisfactory and about 5% yielded an abnormal result. 
Thus, it is important for clients to follow-up on unsatisfactory results. 
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Figure 4.26 Pattern of follow up tests after an unsatisfactory result 
 
Figure 4.27 shows the proportion of women who had a repeat Pap smear test following an 
unsatisfactory result. In the 2001 period, about 50% of these clients failed to follow-up. 
Although the follow-up rate increased in the 2004 period just after the PPCC started, about 30% 
of the clients still did not follow-up with another test within a year.  
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Figure 4.27 Proportion of follow-up tests after the first unsatisfactory result, 2000 to 2010 
 
Figure 4.28 presents the results of compliance analysis by time period. Overall, the two 
periods after the PPCC started had higher follow-up rates (more than 60%) than the period 
before the PPCC began (≈ 50%).  
 Figure 4.29 shows the event density function. Due to the small sample size of women who 
had “unsatisfactory results” for their first tests, the density function for each of the three time 
periods are somewhat variable and difficult to compare. Two trends were observed: (1) many 
clients returned within the first three months following an unsatisfactory rest result; and (2) 
repeat testing seemed to occur in the eigth month.  
Unsatisfactory test results are a very small proportion of general Pap smear screening tests 
(usually less than 1%). Thus, the patterns of follow-up tests after an unsatisfactory result will be 
more variable than the patterns seen after either negative or abnormal-low results. Given the 
smaller sample size for this category of Pap test results, a hazard function analysis was not 
presented here for the three time periods. Trends were similar to the event density analysis (not 
shown). 
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Figure 4.28 Cumulative proportion of returning test following an unsatisfactory result by time 
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4.3.6 Final models to examine the follow-up patterns and risk factors 
As a final step, a multivariable Cox model was constructed to check if the pattern of 
differential participation rates by time period would hold when other risk factors were considered. 
Table 4.5 shows the factors which predict the likelihood of follow-up following the first 
negative test result. Similar to the results of previous analyses, time period was a statistically 
significant predictor of follow-up after adjustment for covariates. Women in both the 2004 and 
2007 periods were less likely to have timely follow-up compared to women tested in the 2001 
period. Between the 2004 and 2007 periods, the likelihood of repeat testing was higher among 
women in the latter period. Both of these observations agreed with the results from the 
“compliance analyses” presented earlier. In Figure 4.14 and Figure 4.15, women were more 
likely to return for repeat testing within twelve months of receiving a negative result in the 2001 
period compared to both the 2004 and 2007 periods. In addition, both client’s age and where they 
lived (rural/urban) were significant predictors of participation (p<0.0001). Older women (i.e., 30-
39, 40-49, 50-59, 60-69 year olds) were less likely to follow-up compared to the youngest 
women (20-29 year olds). Urban-dwelling women were 12% more likely to return for repeat 
testing compared to women from rural areas.  
To allow for the inclusion of SES as a covariate the results shown in Table 4.6 are based 
only on urban-dwelling women. Time period remained a statistically significant predictor with 
women tested in the 2001 period being more likely to return for a follow-up test. In addition, 
older women were less likely to return compared to women in the youngest age category. As the 
neighbourhood income quintile increased the likelihood of return improved. Age-at-screen and 
income quintile were tested as an interaction term but were not found to be significant.  
Table 4.7 shows the results of modeling the effects of time period for women who had two 
consecutive negative test results with age and area of residence as covariates. Age and area of 
residence were both found to be significant factors (both p<0.0001). Time period was again a 
significant factor (p<0.0001), as shown in the “compliance analysis” in (Figure 4.18). 
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Table 4.5. Taking the second test following the first negative test result in urban vs. rural 
 Covariate Covariate levels  Hazard Ratio (95% CI) p-value 
Period of test 
2001  Referent  
2004 0.62(0.60-0.64) <0.0001 
2007 0.66(0.64-0.68) <0.0001 
 
 
 
 
Age 
20-29                  Referent  
30-39 0.62(0.60-0.64) <0.0001 
40-59 0.47(0.46-0.49) <0.0001 
50-59 0.45(0.44-0.47) <0.0001 
60-69 0.36(0.34-0.37) <0.0001 
 
 
 
 
Area of residence 
Rural  Referent  
Urban 1.12(1.10-1.15) <0.0001 
 
 
Table 4.6. Taking the second test following the first negative test result with income quintile in 
urban area 
Covariate Covariate levels Hazard Ratio (95% CI) P-value 
Period of test 
2001         Referent  
2004 0.63(0.61-0.65) <0.0001 
2007 0.68(0.65-0.70) <0.0001 
 
   
Age (years) 
20-29         Referent  
30-39 0.64(0.61-0.66) <0.0001 
40-49 0.48(0.46-0.50) <0.0001 
50-59 0.46(0.43-0.48) <0.0001 
60-69 0.37(0.35-0.40) <0.0001 
 
   
Neighbourhood 
Income 
Quintile 1 (lowest)         Referent  
Quintile 2 1.08(1.03-1.13) 0.0013 
Quintile 3 1.15(1.09-1.20) <0.0001 
Quintile 4 1.22(1.17-1.28) <0.0001 
Quintile 5 (highest) 1.24(1.18-1.29) <0.0001 
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Table 4.7. Taking the third test within 36 months following two negative test results in urban vs. 
rural areas 
Covariate Covariate levels Hazard Ratio (95% CI) p-value 
Period of test 
2001         Referent 
 2004 0.74 (0.73-0.76) <0.0001 
2007 0.82 (0.80-0.85) <0.0001 
 
   
Age (years) 
20-29         Referent 
 30-39 0.74 (0.72-0.76) <0.0001 
40-49 0.67 (0.65-0.69) <0.0001 
50-59 0.64 (0.62-0.66) <0.0001 
60-69  0.45(0.43-0.47) <0.0001 
 
   
Area of residence 
Rural         Referent 
 Urban 1.10(1.08-1.12) <0.0001 
 
The test period remained significant in the multivariable model, with the 2001 period 
having the highest follow-up rate, with the 2007 period experiencing a slightly better repeat 
testing rate than the 2004 period (as shown in Figure 4.18).  
Table 4.8 shows results for women whose first test result was abnormal-low. The effect of 
the testing period remained statistically significant after controlling for the effects of age and 
area of residence. Both the 2004 period and the 2007 period had lower follow-up rates than the 
2001 period. There was no significant difference between the 2004 and 2007 testing periods as 
demonstrated in Figure 4.23 where both curves almost overlap. The effect of age, while 
statistically significant, was in the opposite direction of what was seen with the women who had 
negative (normal) test results (Table 4.5 and Table 4.7). After an initial abnormal-low test result, 
older women were more likely to follow-up with a second test, a trend that was notable for 
women older than 40 years onwards. Women 40-49 years (p=0.02) and 50-59 years (p=0.0007) 
were more likely to return for a second test after an abnormal-low result.  The effect of age on 
return for a second Pap among 60-69 year olds was not statistically significant, probably due to a 
low number of women tested in that age group. After an abnormal-low result, women from rural 
and urban areas were equally likely to return for a second test when age and testing period were 
included as covariates.  
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Table 4.9 describes the effect of income on return testing among urban women. Again, an 
age effect starting from age 40 onwards is evident; older women were more likely to come back 
for a follow-up test. The likelihood of returning for a follow-up test after an initial abnormal-low 
result increased with increasing neighbourhood income. Notably the effect of age return testing 
was attenuated and barely significant once income quintile (SES) was included in the model.  
Overall, unsatisfactory results as a proportion of total results were low (less than 1%). One 
would expect that the impact of these results when examined by time period would be further 
diluted. Therefore, this category of test results was not examined further in this study.  
Table 4.8. Taking the second test following an initial abnormal-low result in urban vs. rural 
Covariate Covariate levels Hazard Ratio (95% CI) p-value 
Period of 
test 
2001          Referent 
 2004 0.85(0.77-0.94) 0.0015 
2007 0.84(0.75-0.93) 0.001 
 
   
Age (years) 
20-29         Referent 
 30-39 1.01(0.90-1.14) 0.82 
40-49 1.18(1.03-1.35) 0.02 
50-59 1.43(1.16-1.75) 0.0007 
60-69  1.23(0.91-1.66) 0.17 
 
   Area of 
residence 
Rural         Referent 
 Urban 1.00(0.92-1.09) 0.94 
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Table 4.9. Taking the second test following an initial abnormal-low result with income quintiles 
in urban area 
Covariate Covariate levels Hazard Ratio (95% CI) p-value 
Period of test 
2001         Referent 
 2004 0.88(0.78-0.99) 0.04 
2007 0.80(0.70-0.92) 0.001 
 
   
Age (years) 
20-29         Referent 
 30-39 1.00(0.86-1.16) 0.97 
40-49 1.17(0.98-1.38) 0.08 
50-59 1.37(1.06-1.77) 0.01 
60-69  1.24(0.82-1.88) 0.31 
 
   
Neighbourhood 
Income 
Quintile 1 (lowest)         Referent 
 Quintile 2 1.21(1.03-1.41) 0.02 
Quintile 3 1.25(1.06-1.47) 0.008 
Quintile 4 1.38(1.17-1.62) <0.0001 
Quintile 5 (highest) 1.39(1.19-1.63) <0.0001 
 
4.3.7 Summary of results for Objective 3 
About 95% of women who administered a Pap smear test received a negative (i.e., normal) 
test result. Of the remainder, a small percentage received an abnormal-low test result (3-5%) and 
even fewer received an unsatisfactory test result (less than 1%).  
Testing time period was strongly associated with follow-up patterns in both descriptive and 
multivariable analyses. More specifically, follow-up rates tended to be lower in both the 2004 
and 2007 periods (after the PPCC was implemented) than in the 2001 period. The results of the 
multivariable analysis suggested that the relationship between area of residence (urban/rural) and 
follow-up varied by test result: urban women were more likely than rural women to return for 
testing when the first test results were negative or following two negative test results; no 
urban/rural differences emerged for follow-up testing after an initial abnormal-low result. A 
differential effect on return testing by client age group was observed according to whether the 
first test result was negative or abnormal-low. In addition, among urban women, higher SES was 
associated with a greater likelihood of follow-up testing.   
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CHAPTER 5 
 DISCUSSION 
First, this chapter summarizes the main study findings and then compares and contrasts 
these findings using relevant studies from the literature. Possible explanations for these findings 
are also discussed. Next, the strengths and limitations of this study are highlighted. Third, 
suggestions to increase Pap smear participation rates are explored. Finally, future research 
questions are proposed at the end of the chapter. 
5. 1 Summary of main findings and comparisons with the literature 
        There were a number of key objectives associated with this research. First, the impact of 
introducing the PPCC on screening participation and retention was evaluated. The second 
objective was to examine whether Pap test participation differed between women who resided in 
urban and rural areas. Further this thesis attempted to answer the following question: of those 
women who lived in urban areas did socioeconomic status influence their participation? The 
final objective explored the follow-up patterns of women who had one or more negative test 
results and abnormal-low result. The following sections will compare and contrast the findings 
with the literature as well as provide explanations for the findings.                 
5.1.1 Evaluating the impact of introducing organized screening through the PPCC in 
Saskatchewan  
Cervical cancer screening data trends in Saskatchewan (2000-2011) demonstrate the impact 
that the PPCC has had in altering population screening behaviour measured by participation rate 
trends. The participation rate encompasses both initial and return tests. Shortly after its inception, 
the PPCC participation rate spiked at 64.7%. There were an increasing number of initial and 
repeat Pap tests following a normal result (i.e., retention) that seemed to encourage appropriate 
use of the test while maximizing participation.  
Over the next eight years however (2003-2011), participation and retention rates have 
gradually decreased. Due to a decrease in the number of initial participants from younger age 
groups, participation has decreased at a faster rate than retention as the latter only includes 
women who have already had a negative (normal) test result. By 2009-2011, participation 
decreased to 60.9% lower than before the PPCC was launched (62.7% in 2000-2002). There are 
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a number of reasons that could partially account for this participation decline either individually 
or in concert as discussed below.  
5.1.1.1 Initial, re-screen Pap tests and declining participation 
Motivation to participate in cervical cancer screening would have been high immediately 
after the Cervical Cancer Screening Task Force was established in Saskatchewan (1998). During 
the lead up to program implementation and in its early years, the PPCC engaged multiple 
stakeholders through physician and provincial lab newsletters, various media campaigns and the 
use of initial invitation and subsequent client recall letters. These actions had the desired effect of 
improving programmatic participation (2002-2004) resulting an increase in participation. As the 
program grew, motivation to undergo screening seemed to decrease, reflected in decreased 
participation. The focus seemed to gradually move away from recruiting initial first time clients 
and towards retaining clients.  
This is reflected in a decrease in age-specific participation with the greatest drop in the 
youngest age group i.e., among initial participants. Since 2006, the number of initial screeners 
(first Pap test) has stabilized at about 1,200 to 1,300 clients; this seems to suggest that declining 
participation involves clients not returning to screen (rescreen). Efforts to emphasize the 
importance of regularly screening at recommended intervals may have had unintended 
consequences.  
  The relationship between the participation rate and client non-compliance with the 
recommended screening interval can be explained using the two different types of letters that are 
sent to PPCC clients. The initial invitation letter (Letter A) asks women to participate in the 
PPCC for the first time, conveying the importance of attending screening or simply serving as a 
reminder. Following a screen about 95% of women receive a result letter (Letter B) indicating a 
normal (i.e., negative) result. At the same time, the result letter also specifies a recommended 
recall interval. Every time a result is received following a Pap test, a time interval to the next 
screen time is indicated. However, this interval varies as a function of the initial timing of the 
Pap test, its results and the prescribed screening guidelines. For example, if this was the client’s 
first result the letter may ask them to return in a year. On the other hand, if a client has had two 
consecutive normal test results, clinical guidelines recommend that her next screen should occur 
after three years. Since the introduction of the PPCC, the ratio of women receiving a result letter 
(letter B) with a three-year screening interval for her next screen to those receiving an invitation 
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letter to undergo screening for the first time (letter A) has been increasing. Generally, letter A 
would be sent to initial participants – either clients who just turned 20 years or to new residents. 
Letter A targets eligible women who have never attended the program and thus seems to increase 
participation. Result letter B reminds PPCC participants of their next appropriate screening 
interval, typically in three years after two consecutive normal screen results.  
From a behavioural perspective, several consecutive normal results could signal to a client 
that her cervical health is satisfactory and that further Pap testing is optional. Some clients may 
return annually or have repeat tests as recommended but others may delay repeat testing. These 
accumulated delays among many clients reduces triennial participation compared to the 
alternative where clients return to screen within the recommended three-year interval (refer 
Figure 4.20). Result letters may have the unfortunate effect of understating the urgency of repeat 
screening, by recommending that clients return to screen within three years after two consecutive 
normal results. These findings may also be used to predict similar declines in participation for 
other programs that send such mixed messaging.  
In contrast, the Manitoban CervixCheck program sends result letters to clients where the next 
recommended Pap test date is not explicitly mentioned.   
This implies that participation will continue to decrease a fact supported by recent data. 
Crude 2011-2013 participation is at 57.8%, the lowest proportion participating since 2000-2002 
(source: internal PPCC quarterly report). Conversely varying time intervals depending on test 
result may also be confusing and some women prefer to ignore these and get screened once a 
year to make sure they have done everything possible to stay healthy. Societal trends also 
encourage more independence and free choice, resulting in tenuous adherence to clinical 
guidelines. All these situations may reinforce non-compliant behaviours. 
There is a gap between the intent and rationale that the result letters try to convey and 
subsequent client action that manifests as a drop in participation. These situations can be 
summed up in the context of the Theory of Planned Behaviour (TPB).
231
 The TPB suggests that 
an individual’s screening behaviour is determined by their intention. This intention is a function 
of subjective norms (e.g. beliefs), their attitude towards screening and perceived behavioural 
controls. While it is relatively difficult to influence the former factor the latter two factors can be 
influenced through the use of letters. Generally the more favorable a client’s attitude towards 
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screening, the stronger will be their intent to return to screen. Perceived behavioural control 
refers to people's perceptions of their ability to perform a given behaviour.  
Attitude and behavioural controls can be influenced by client interactions with their family 
physician. As the average age of family physicians in Saskatchewan is over forty-five years of 
age, many may have been trained in the era of opportunistic screening,
232
 where an annual recall 
cycle was the norm. Thus it is possible that physician training plays a major role in influencing 
client return to screen on an annual cycle versus the currently recommended three-year interval. 
Educating the physicians and/or the clients on the rationale and benefits behind screening on a 
three-year interval after two consecutive normal results may help in improving compliance. 
Another possible policy direction to improve physician compliance could be a change in billing 
procedures wherein return on an annual cycle except where recommended would not be 
reimbursed at the same level as return to screen on a three-year interval.  
The results presented here seems to indicate that the PPCC’s current letters as designed 
may influence client behaviours in a ways that may go against what the clinical guidelines were 
expected to elicit. A focus group or survey may serve to clarify clients’ perceptions regarding the 
content of both letters and the messages that each letter sends. Other obstacles may be uncovered 
as well. For example, an unknown in this study is the influence that health care providers have 
on cervical cancer screening participation and retention.  
Since there was a lack of access to physicians billing data this aspect could not be explored. 
In light of the guiding conceptual model, the provider level was not included in analysis for 
practical reasons but definitely plays a role in providing access to the test. More in-depth 
exploration would help tailor appropriate changes at the system level and solicit additional 
cooperation at the health care provider level in order to deliver screening intervention more 
effectively. 
5.1.1.2 Impact of a growing population on the PPCC participation and retention rates 
The growing age-eligible target population could have also had an impact on participation 
trends. The target population (20-69 years) gradually increased from 304,220 in 2000 to 341,294 
in 2011. Part of this increase was due to greater in-migration to the province within Canada and 
also due to immigration.  
In general immigrant women are less likely to participate in cervical cancer screening due 
to language barriers and differences in cultural background. This was shown in a recent study of 
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immigrant women in Ontario.
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  However, the impact of immigration is expected to be minimal 
in this analysis for the following reasons: (1) immigrant women in the target age group only 
make up 0.85% of the total age-eligible population in Saskatchewan in 2011; and (2) 
immigration levels to Saskatchewan were even lower prior to 2011 (average: 0.21%).  
5.1.1.3 Impact of age-at-screen on PPCC Participation Rates 
Participation rates from 2003 to 2011 fell in every ten-year age group (i.e., 20-29 years, 30-
39 years, 40-49 years, 50-59 years and 60-69 years). Younger age groups were found to have 
higher participation and retention rates. Trends in Saskatchewan follow those nationally. Two 
national cervical cancer screening reports from the Canadian Partnership Against Cancer 
(CPAC)
222,223
 showed that Pap test uptake decreased as the age of the participants increased 
(from 20-29 year olds to the 60-69 year olds). The 2009-2011 data showed the age specific Pap 
test participation rates gradually decreased from 80.1% in 20-24 year olds to 47.2% in 60-69 
year olds. Younger women are more sexually active, take birth control pills (oral contraceptives) 
and have pre/post-natal care; these situations may result in women having a Pap test after 
consecutive normal tests outside recommended clinical guidelines.  
Uptake among 20-29 year olds dropped from 81% in 2002-2004 to 75% in 2009-2011. 
There are several reasons for this trend. Younger women are more prone to barriers to initial Pap 
testing including fear of pain, discomfort, embarrassment and general procrastination.
234,235 
As 
well, young women increasingly have the perception that cervical cancer would not affect them 
at a young age, a notion probably reinforced by normal results from the PPCC coupled with a 
three-year recall interval. A focus group study in Sweden showed that young women (i.e 30-
year-olds) do not think that they would get cervical cancer making screening low on their list of 
priorities.
236
 These attitude changes may result in a decline in repeat testing and participation.  
Participation in the 60-69 year age group in the same period was the lowest of all the age 
groups (42%). This trend is also seen in a number of other screening program reports.
144,237
 Older 
women may think that the Pap test is no longer required at their age or even superfluous given 
their lower level or absence of sexual activity. Physicians may also become hesitant to offer the 
test due to their own beliefs or lack of comfort with such a procedure in older women. 
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5.1.1.4 Impact of age-at-screen on PPCC Retention Rates 
A similar pattern was observed for retention. A greater number of younger participants (20-
29 years) returned for repeat Pap tests compared to older participants (30-59 years and 60-69 
years) for all the screening periods considered. In this analysis, there was a retention rate 
gradient observed for clients at the time of screen. This trend matches CPAC reports. Nationally, 
retention ranged from 81.8% in 20-29 year olds to 72.2% in 60-69 year olds (2004-2005 data) 
with similar trends seen in 2007-2008 data. The reasons for declining retention are similar to 
those for participation rates. Although age-specific retention in Saskatchewan was lower than the 
Canadian average the trend remained the same.  
The largest fall in retention when comparing 2002 rates to 2008 rate was among 60-69 year 
olds (approximately 7%). A lower proportion of older clients returned for repeat Pap tests. 
Overall, the decrease in retention was much more modest after 2003 reaching a plateau of 74.5%. 
This means that younger participants were returning for screening but as they got older they 
stopped coming back.  
5.1.1.5 Reasons for declining retention trends 
There are a number of possible factors that could explain this trend. These factors can 
operate at the individual or system level according to Zapka’s conceptual model.30 There is an 
association between the client’s attitudes towards their general health and their screening 
behaviours.
238
 First, client attitudes towards screening and general health behaviour may vary by 
client age.
239
 Younger clients are more likely to engage in healthy screening behaviours than 
older clients for reasons discussed earlier. Also as younger clients are more sexually active, 
clinical practice guidelines require that they receive a Pap test prior to being prescribed oral 
contraceptives. This contributes to higher participation and retention particularly in the 20-39 
year age group.
18
 Next, it is plausible that as clients get older and receive more normal tests 
results they lose the motivation to return for regular testing. Perhaps older clients believe that 
consecutive normal tests are indicative of adequate or good cervical health and that future testing 
is optional. However, it is likely that family physicians may be more interested in examining 
clients in this age category for cancer. Also it is known that hysterectomy rates (at the system 
level) are higher in women as they age. It is expected that older women have a greater proportion 
of the hysterectomies than the younger women, thus contributing to a reduction in the 
participation and retention rates as clients’ age.  
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Note that in this dissertation, participation rates have not been corrected for hysterectomy 
prevalence. Women who have had a hysterectomy are not eligible to be screened thereby 
reducing the denominator and increasing the Pap smear participation rate in the same period. 
Internal Saskatchewan Ministry of Health information (personal communication) estimates that 
there were about 33,000 hysterectomy procedures done for women aged 69 years or younger 
from 1987 to 2008. This puts the prevalence of hysterectomy in the province over 10%. Further, 
most hysterectomies would likely occur in women older than 40 years of age. Younger women 
are less likely to have hysterectomies, highlighting the effect among the older age groups. After 
correcting for hysterectomies the Pap test participation rate would be a little over 70% among 
eligible Saskatchewan women in the target population (20-69 years). Randomized trials have 
estimated that a participation rate of 70% or over is associated with significant reduction in 
mortality.
2,240,241 
  
Although the focus of this analysis is the three-year rolling participation rate, other 
jurisdictions may use varying definitions for participation due to differing clinical guidelines. 
This can affect reported participation and comparisons. For example, in England, recall intervals 
differ by age group: three years for women between 25-49 years and five years for 50-64 year 
olds.  
In this study, if participation was defined as a test completion in any given five year period, 
the rate would likely increase as women who delay returning to test after for a negative result 
would be included. If the participation is based on “ever participating” in cervical cancer 
screening in one’s life time, then participation can even exceed 90%. This would imply that 92% 
of women in the target population would have received at least one Pap test in their lifetime.  
Participation rate calculation is done on a three-year rolling basis to match clinical 
guidelines, given that 95% of clients have consecutive normal results. The three-year interval 
was chosen as a tradeoff to reduce the number of Pap tests thereby reducing system costs while 
still achieving an appreciable decrease in incidence (i.e., 90.8% according to studies).
36
 As many 
PPCC clients do not return within the specified three-year interval it is likely that theoretical 
incidence reductions would take much longer to achieve in practice. This is supported by 
cervical cancer incidence rates in Saskatchewan that have remained relatively flat since PPCC 
inception (2003-2011).  
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5.1.4 Repeat Pap smear testing patterns after an abnormal test result 
Abnormal-low test results in the youngest age group are likely driven by a higher level of 
sexual activity common in this age group. In this age group, abnormal-low test results are most 
likely false positives where recovery is likely without further treatment (HPV+).
2,242,243
 Therefore, 
physicians would be less likely to encourage clients in the youngest age group with an abnormal-
low test result to come back for repeat confirmatory testing. This trend is confirmed in the 
literature. A study by Jones et al found that younger clients (<=30 years) were significantly less 
likely to have a follow-up test than those who were older when they were diagnosed as 
abnormal-low grade and abnormal-high grade.
244
 
Older clients were more likely to follow-up on an abnormal-low test result compared to a 
normal result. In addition, physicians play an important role in influencing a client’s decision to 
have a follow-up test after an abnormal result. This may be in part due to physician attitude 
towards repeat testing depending on client age group. As discussed before, after a normal test or 
two consecutive normal test results, an older client would be less likely to come back for repeat 
testing compared to clients in the youngest age category (20-29 years; referent). However, this 
trend is reversed when the test result is “abnormal-low”. Here, older women are more likely 
come back for a follow-up test compared to women in the youngest age category (20-29 years; 
referent). This finding influences repeat testing patterns and explains the contribution of older 
women to a higher follow-up rate. 
Among older women (30+ years), it is possible that this is either their first Pap test or more 
likely that they have not had a Pap test for a prolonged period i.e., the recommended screening 
interval was not followed. Cervical cancer incidence peaks among females after 30 years. The 
literature also supports this trend. Gustafson et al found that there is a rapid rise in cervical 
cancer incidence in women between 30-40 years and that incidence peaks in the 44 to 49 year 
age group.
245
 Saskatchewan age-specific incidence rates also follow a similar trend with the rate 
in the 44-49 year age group being 17.1 per 100,000 women in 1990-2010. Physicians may be 
more active in following up older women (30+ years) when they test positive (abnormal-low). 
An analysis by Bhogireddy reported that women 35 years and younger are more likely to be 
diagnosed with an abnormal-low grade result (30%) compared to women older than 35 years 
(14%). Histology reports from the same paper showed that women older than 35 years with 
abnormal cytology results presented with more severe histology lesions than women younger 
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than 35 years.
246
 This could account for physicians being more active with following-up older 
women.
2,143
 In addition, client attitudes regarding abnormal results could also influence the study 
findings. Cancer is a disease largely occurring among older people. Thus, older women would 
probably be more motivated to resolve an abnormal test result compared to younger women. 
5.1.5 Rurality, socioeconomic status and Participation 
This analysis found that rural women were less likely to participate in cervical screening 
compared to their urban counterparts. This finding is supported by studies in the literature. For 
example, a study in Manitoba by Young et al used administrative databases to analyze the 
prevalence of Pap testing in 1993-94 to 1995-96. This study found that age-standardized Pap 
testing rates were higher in Winnipeg (urban) compared with southern rural and remote northern 
Manitoba. Further, the difference between Pap test rates in urban and rural areas may be an 
underestimate as Pap tests performed in northern Manitoba are done at nursing stations which is 
not captured in medical claims data.
157
 Similarly, in a study sponsored by the Canadian Institute 
for Health Information (CIHI), using data from the 2000-2001 Canadian Community Health 
Survey, a significantly lower (age-standardized) proportion of rural compared to urban 20-69 
year old women reported having had a Pap test in the last three years.
247
 Further, compared to 
urban-dwelling women, cervical cancer incidence rates were higher among women in the most 
remote regions of Canada, and among 20-44 year old women remote-dwellers experienced a 
higher mortality rate due to cervical cancer. More recently, a retrospective cohort study linking 
administrative and survey data in Ontario found increasing levels of rurality to be associated with 
a decreasing probability of being correctly screened for cervical cancer according to provincial 
guidelines.
248
 The results of a number of studies from the United States also suggest that, on 
average, rural dwelling women have lower cervical cancer screening rates that urban women, 
though quite complex and diverse results emerge when ethnicity and region are also 
considered.
249,250
  
Although urban/rural differences in the prevalence of Pap testing have emerged in a 
number of Canadian studies and elsewhere, limited research has systematically examined the 
factors which might underlie these differences. Pap test participation rates in rural areas are 
likely influenced by a number of factors that can operate at the system, provider and individual 
client levels according to Zapka’s conceptual framework guiding this dissertation.30 Access to 
health care clinics is regulated by factors at the system and provider levels, especially in rural 
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areas. Systemic factors include the number of clinics in an area. Provider factors include the 
number of physicians available in an area to perform a Pap test. Women in rural areas may not 
have easy access to health providers as there are a lower number of health providers. Some 
research from the United States suggests lower screening rates for women without a regular 
health care provider, those living in locations with fewer primary care facilities, and among those 
living furthest from medical clinics.
249,250
 In Canada in 2004, 9.4% of physicians practiced in 
rural areas (approximately 16% of family physicians and 2% of specialists) even though more 
than one-in-five Canadians lived in non-metropolitan areas of the country.
251
 Despite these 
statistics however, the results of Canadian studies comparing health care access by urban/rural 
status have not produced consistent results, with considerable variation in findings according to 
how health care access and rurality are operationally defined and what other characteristics are 
included in the study, including province.
252
 The most consistent findings that have emerged in 
the Canadian literature are that rural Canadians have less access to specialist services compared 
to their urban counterparts but do not appear to differ in their access to family 
physicians.
247,252,253
    
In a study specifically looking at Pap test utilization among Manitoba women, Decker and 
colleagues reported, similar to previous research, that urban women had a significantly higher 
rate of Pap test screening compared to rural women; however, urban and rural women 
experienced a similar number of opportunities (i.e., physician visits) for cervical cancer 
screening.
145
 The same study also reported that rural family physicians were less likely to 
provide a Pap test than specialists or urban family physicians. Some research suggests that health 
care provider characteristics associated with lower screening rates in general population samples 
may be more prevalent in rural compared with urban settings. For example, research suggests 
that female physicians’ patients are more likely to be screened for cervical cancer than those of 
male physicians’, as are patients of specialist physicians compared to general 
practitioners.
137,138,139,140,145
 Some limited evidence also suggests that international medical 
graduates practicing in Canada may be less likely to conduct cervical cancer screening compared 
to graduates of Canadian medical schools.
254
 Women physicians comprise a smaller proportion 
of physicians in rural compared to urban Canada; conversely, foreign trained physicians 
comprise a larger proportion of the rural than urban physician workforce in Canada.
251 In 
addition, as previously mentioned, specialists are more prevalent in urban compared to rural 
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locations in Canada. These provider characteristics may contribute to lower cervical cancer 
screening rates in rural compared to urban settings.  
Individual factors can also influence client participation in Pap test screening. Some of 
these factors include clients’ socioeconomic circumstances, as well as health status, beliefs and 
attitudes towards screening, cultural beliefs, and comfort level toward the test itself, among 
others.
255
 A Serbian study found that women in rural areas were much less likely to attend Pap 
testing within the last 12 months when compared to women residing in urban areas.
256
 Another 
study found that women who live in a rural areas are more likely to be older, less educated and 
poorer (lower SES). Such women typically find it harder to access health care facilities.
257
 
However, several studies have reported that the lower screening rates observed in rural compared 
to urban areas persist even after controlling for urban/rural individual differences in social, 
economic, and health status characteristics.
248,258
   
This dissertation demonstrated that in urban areas, age-standardized screening participation 
rates increased with increasing neighborhood income quintile (Q1-lowest; Q5-highest) with 
significant differences in uptake and repeat testing detected between the quintiles in the 2005-
2007 period. The positive, graded association between SES and cervical screening observed in 
this study (i.e., higher SES, higher participation) has been similarly reported in an extensive 
array of studies, both in Canada
259,260
 and other developed countries,
162,164,261
 using a variety of 
SES indicators.  
It can be challenging to explain such a gradient, particularly within a country such as 
Canada which boasts a universal health care system. Common indicators of SES, such as 
household income and educational attainment, are considered markers of an individual’s degree 
of access to various health enhancing material and psychosocial resources.
262
 Regarding material 
resources, it is possible that economically disadvantaged women may find it challenging to 
afford transportation to attend screening appointments or provide for child care, or have the job 
flexibility needed to take time off work in order to participate in screening.
248,250
 Regarding 
psychosocial mechanisms, low SES may be associated with a number of personal characteristics 
which might decrease the likelihood of screening, including more limited awareness of the 
benefits of participating in screening, more fatalistic beliefs and feelings of powerlessness, and 
greater embarrassment of the screening procedure itself.
29
 A study by McCaffery found that 
individuals in the lowest SES category were more likely to regard any new preventive regime 
105 
with some suspicion. This might reflect lower levels of trust in the health care system as these 
individuals typically report bad experiences with medical staff and hospitals that can influence 
their attitudes towards screening.
263
 In addition, individuals at lower SES would likely 
experience significant barriers to screening and may be less likely to read educational 
information sheets related to health prevention and promotion even if the material was simple 
and attractively presented.
264,265
 Thus, both material and psychosocial mechanisms may be 
important in trying to understand lower cervical cancer screening rates among lower SES women. 
  
In this body of literature, many of the studies reviewed used individual/household-level 
indicators of SES, particularly educational attainment and/or household income. More recently, 
area-level measures of SES have become more prevalent in the literature, such as the one used in 
the present study (neighborhood income quintile). Consistent with the results of this study, a 
recent study out of Ontario reported a graded, statistically significant association between higher 
neighborhood income quintile and greater likelihood of receiving one or more Pap tests in the 
last three years, with participation rates ranging from 61% in the poorest neighborhood to 75% in 
the richest neighborhood.
266
 Similar findings have been reported in Australia
162
 and in the United 
States.
267,268
  
However, compared to research using individual and/or household level-indicators of SES 
in relation to cervical cancer screening participation, much less is known about the mechanisms 
linking area-level indicators of SES and screening behaviour.
269
 One criticism of this body of 
research is the lack of explicit conceptualization by researchers regarding what area-level 
indicators used in their study actually represent. Area-level data are sometimes considered as 
proxy measures for individual/household-level SES. Alternatively, use of area-level indicators 
can be viewed as an attempt to move beyond the individual or household-level to capture 
contextual or place influences on health. Regarding the latter, it has been suggest that area-level 
indicators of SES may reflect characteristics of neighborhoods such as social cohesion, 
behaviour norms, or even availability of health care facilities, which may in turn may influence 
screening behaviours.
269
 Although relatively few studies on cervical cancer screening have 
employed both individual-level and area-level measures of SES in the same study, those which 
suggest that the social and economic characteristics of neighborhoods may have an impact on 
screening behaviour above and beyond individual/household level SES. For example, a recent 
study from the United States reported that women with low educational attainment and who lived 
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in a neighborhood with a low percentage of educated residents were less likely to have received a 
Pap test compared to low educational attainment women living in other neighborhoods.
261
 
Another study found a statistically significant association in neighborhood household median 
income while controlling for individual level covariates like age, individual education, ethnicity 
and employment (p<0.001). Here, women from households with higher median household 
income (> $53,099) were 34% more likely to follow-up on abnormal screening result compared 
to clients from lower median income households (<$36,147).
270
 
5.2 Strengths & Limitations 
            The strengths of the approach taken in this thesis are as follows:  (1) Use of longitudinal 
data: Analysis was done with administrative data that had longitudinal follow-up. This data 
included complete information on clients’ birthdates, Pap test dates and associated cytology 
results; (2) Longevity of database: The PPCC is a population-based (organized) cervical cancer 
screening program covering all age-eligible (target population: 18-69 years) Saskatchewan 
women. An invitation letter is sent to all eligible women. It started off in 2003 as an organized 
program where screening services are of high quality and are checked and monitored. In such 
programs, everyone who takes part is offered the same services, information and support. Most 
of the other organized screening programs in Canada started off as partially organized programs; 
(3) In this dissertation the results obtained are consistent when using both spline and survival 
analysis techniques; (4) This dissertation is one of the few studies that examines patterns for 
repeat Pap testing after normal and abnormal-low results unlike other studies that group result 
types together; (5) The PPCC is one of the few organized screening programs that has used 
letters to invite and remind women since its inception in 2003. Using data from such a program 
to analyze client repeat testing behaviour is a novel feature of this study; (6) This analysis 
utilizes multivariable regression methods to analyze the association of SES and screening 
attendance in the context of an organized program.      
            It is recognized that there are many limitations within this research: (1) The colposcopy 
follow-up data for clients with abnormal-high test results was not available. While this 
information is important it was not analyzed due to unavailability of data; (2) Cytology result 
data was unavailable before 2000, limiting the ability to detect trends over a prolonged period. 
However there is little reason to believe that these trends differ from the period immediately 
before PPCC started as presented in this dissertation. As seen in this study, many women who 
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participated in the early years after the PPCC started clearly were not first time participants. 
These women may have had their first “true” Pap test prior to the introduction of the program. 
This could confound the relationship between time period and client repeat resting and retention; 
(3) Complete data was not available for women between 18-19 years for all screen years. In this 
dissertation, the target population was between 20-69 years but invitation letters were sent to 
women when they turned 18 years old. Thus, this analysis may not be considering the client’s 
first Pap test; (4) There is limited information on client’s education and ethnicity; these factors 
have been shown to influence screening participation but are not collected by the PPPC; (5) 
Postal codes that were missing at the time of the Pap test were replaced by the client’s current 
postal code. The impact of this misclassification is expected to be minimal as only ~2% were 
missing in the analysis period (2005-2007); (6) Income quintiles for rural areas could not be 
determined. Income quintiles from the PCCF+ for rural areas can be misclassified;
228
 (7) 
Analysis at the provider level was not possible as complete data was not available. All these 
limitations need to be kept in mind to remind the reader to be cautious about the findings. 
5.3 Future Research  
5.3.1 Exploring new ways to enhance the PPCC  
As Saskatchewan’s Pap test participation is lower than the national average, it would seem 
prudent to focus on women who have never taken the test (i.e., unscreened) or undergo screening 
infrequently. A key method used by the PPCC to increase participation has been to proactively 
send invitation, recall and reminder letters. However, there might be other methods that can help 
increase the participation rate. One method is to use telephone calls to reach out to those who 
have never participated in screening or have not taken a test for a long time. There is substantial 
evidence available in the literature demonstrating that proactive telephone calls can increase 
program participation.
271,272,273
 This goes a step further than just sending a letter, because a 
telephone call can be more personal than a written note.
274,275
 Such a personalized interaction 
between clients and a nurse could improve awareness regarding cervical cancer screening. 
Ethical issues related to the disclosure of personal health information and the use of telephone 
numbers in the PPCC database need to be resolved before this method can be adopted.  
It is well known that physicians can influence client attitudes towards screening and 
therefore their participation and retention. Many family physicians were trained in the 
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opportunistic testing era before the program began where annual recall cycles were the norm. 
Thus, changing provincial policy to reduce reimbursement for or to only reimburse general 
practitioners for Pap tests done in compliance with the 2003 clinical guidelines may promote 
more appropriate use of the Pap test provincially. Other Canadian provinces are actively 
exploring this approach.  
At the same time, monitoring of clients’ cervical health should be enhanced. Linking health 
care provider and PPCC databases will facilitate better communication regarding appropriate 
clinical screening guidelines and allow the PPCC to collect more relevant data on the quality of 
Pap testing. This would serve the dual purpose of reducing unnecessary tests but also free up 
resources to accommodate infrequent screeners or previously unscreened women.  
Another approach is the use of monetary incentives at the system level to encourage clients 
to take the Pap smear test or to return for follow-up tests in a timely manner. This intervention 
should be relatively simple to implement as it could be done in conjunction with the letters 
regularly mailed to clients. Financial incentives have been shown to be an effective method to 
change client health behaviours, including participation in cancer screening.
276,277,278
 These 
incentives have been shown to be particularly effective in improving access among low SES 
populations and in remote/rural areas.
 279
 
 
In low SES or remote areas, both health equity and 
cultural factors may be barriers to participation. Allocating greater resources to organizations 
like the Pap Test Clinic Network (PTCN) to train community nurses to perform Pap tests in such 
areas could prove beneficial in such instances. These financial incentives in conjunction with 
client navigation may encourage clients to not only participate but facilitate case resolution in a 
timely manner thereby improving retention.  
Increasing the number of female health care providers can promote comfort with and 
reduce embarrassment during the testing process thereby reducing barriers to screening 
participation. In addition, incentives should be offered to female general practitioners to 
encourage them to settle in rural and remote areas to augment services in such regions. This sort 
of provider-level intervention could also be supplemented with further studies on physician 
characteristics and their influence on screening participation.  
Prior to the implementation of any intervention, it would be advisable to test interventions 
using randomized trials.  As the new methods tested go beyond what the current level of service 
offered by the PPCC it seems ethically justifiable to conduct such a study to evaluate 
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effectiveness. Randomized trials reduce opportunities for bias and are the best way to determine 
the causation for any group difference. Alternatively, this idea can be tested by selecting one 
particular group without randomizing.  For example, monetary incentives (e.g., a small chance to 
win a sizable prize)
280,281
 can be utilized as a means to promote participation in rural areas. If this 
leads to a large increase in participation rate in rural areas while there is no such change at the 
same time in an urban area, then there may be good reason to conclude that the financial 
incentive works. This hypothesis can be further verified by applying the same incentives to those 
living in urban areas. Although this study would be observational, it may still provide insight 
into the influence of financial incentives on Pap test participation. These suggested measures 
should improve and promote the efficient use of resources to improve programmatic 
participation and quality of service delivery across the province.  
Many studies have stated that conventional cytology has a low sensitivity. Liquid-based 
cytology offers the potential for improved test specimen collection, but its effect on screening 
test performance remains uncertain. Liquid-based cytology does not differ from conventional 
cytology in sensitivity, specificity or relative CIN detection but yields a lower proportion of 
unsatisfactory slides.
282,283
 Numerous studies have confirmed that HPV testing is more sensitive 
than cytology, but with a tradeoff in terms of reduced specificity.
284
 A review study 
demonstrated that HPV testing sensitivity for CIN3 ranges from 86% to 97%, versus 
conventional cytology range from 46% to 50%. However, the specificity for CIN2 and CIN3 was 
consistently three to five percentage points lower for HPV testing than for cytology.
285
 On the 
basis of large randomized controlled trials, primary HPV screening seems very promising, 
particularly when coupled with reflex cytology to triage positive results before colposcopy. In 
this way screening with HPV testing can enhance the detection of CIN2 and CIN3 cases.
286,287 
The high sensitivity of HPV testing may be beneficial to residents of rural and remote areas 
because of overall lower access to the Pap test. Given that most of Saskatchewan is rural or 
remote, this testing strategy could prove to be important since many women may only have one 
lifetime Pap test; hence using the HPV testing can potentially save their lives.
51
  
The literature has found that self-administered HPV testing was acceptable for women who 
are reluctant to attend cervical cancer screening. Interestingly, these studies found no significant 
sensitivity difference between the clinician and self-administered HPV tests for women with 
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high-grade disease.
288,289
  Research should explore the feasibility and acceptability of such 
testing in Saskatchewan. 
The PPCC clinical guidelines for cervical cancer screening have changed since January 
2012. One future direction for research would be to compare the impact of the introduction of the 
2012 clinical guidelines versus 2003 guidelines on Pap test participation.  
Further, it is crucial for the PPCC to focus on collecting synoptic colposcopy and 
histological data in an electronic format in order to be able to link screening behaviours and 
cancer outcomes. Approximately five percent of women receive an abnormal cytology result 
following their Pap test. Abnormal results and the reporting of their follow-up affect the 
reporting of cancer burden. Currently compliance statistics are unavailable as to whether women 
who receive an abnormal screen result, follow-up with a colposcopy procedure as recommended. 
However these data currently exist as static scanned electronic documents. The PPCC has an 
opportunity to use these existing data to retrospectively study the long-term impact of follow-up 
compliance on cervical cancer rates through manual data re-entry in an electronic format. From 
now on the PPCC should make a concerted effort to electronically collect and tie follow-up 
procedure data (i.e. colposcopy and histology) with screening visits.  
5.3.2 The conceptual framework revisited  
           The factors influencing screening behaviour operate at the health care system, provider 
and client levels. However the success of the PPCC needs to be revisited in the context of the 
conceptual framework used in this study. 
The use of invitation, recall and result letter protocols to implement clinical guidelines by 
the PPCC may have unintentionally sent conflicting messages to the target population. The initial 
invite letter emphasizes the urgency to participate, while recall letters suggest that continued 
participation is optional after a three-year interval. As annual Pap testing behaviours prevalent 
prior to the inception of the program  
The attitude and behaviours displayed by health care providers towards continued Pap 
testing may have also played a role in declining participation rates. This study does not include 
information on the sex, specialty and location of practice of the health care provider. Female 
physician recruitment to rural and remote areas remain challenges that the Ministry of Health 
must address in conjunction with the health regions to improve screening rates.  
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Only few variables were available from the administrative data used to assess factors 
influencing participation at the client level. Even these variables had some blind spots. For 
example, resistance to change well described in the literature and the motivations to take one’s 
health in hand were not evaluated. These factors are strongly associated with younger age, 
education, self-efficacy, knowledge and easy access. At all three levels that constitute the 
conceptual framework further research is required.  
5.3.3 Other research questions 
This study focused on analyzing the impact of the PPCC on population screening behaviour 
during its first decade of operation. The hypotheses outlined in the research objectives assumed 
that all rates would go up or at the very least they should not go down. Even if participation rate 
went down it was not hypothesized to be attributable to the PPCC. The explanation is that the 
ratio of recall to invitation letters serves as a predictor for decreasing participation rates. 
Although the explanation put forth in this thesis may seem oversimplified, it serves as a starting 
point for further research. One possible study to test this working hypothesis is to examine the 
data from other provinces where they have adopted similar guidelines as those used in 
Saskatchewan. They might have started earlier than Saskatchewan, but if these programs send 
mixed messages about the urgency of participating in screening they should produce similar 
results. A focus group or client survey can be conducted to determine the attitudes of women 
towards screening and repeat testing after consecutive normal results. It is also possible that 
removing wording pertaining to the next appointment time frame as is the case in Manitoba’s 
CervixCheck program could correct this aspect. This intervention could easily be tested. 
Another follow-up study would be to assess to what extent changes in cervical cancer 
incidence and mortality over the last decade in Saskatchewan are related to the PPCC’s efforts. If 
there has not been a change in the mortality rate, then it may not be as important that the 
screening participation rate has declined. In fact it might even be argued that a reduction in 
participation rate is a desirable outcome because it reduces multiple testing and diagnostic costs 
associated with investigating false positives. Herbert et al’s study reported that cervical cancer 
incidence dropped when the coverage of women who had at least one Pap test increased even 
though the screening interval increased. Here, a greater number of interval cervical cancers 
(cancer cases diagnosed between scheduled screening episodes) occurred when the 
recommended screening interval was more than 5.5 years. These interval cancers were more 
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likely to be symptomatic and diagnosed either as in situ or at stage I.
290
 The MMWR reported 
that within three years of a normal Pap test result, very few severe abnormal high results were 
reported and that the incidence rates of cervical cancer were similar among women who had 
screening interval in one, two, three years following a normal Pap test.
291
 Many studies have also 
suggested that a less frequent test schedule might be more efficacious in lowering cervical cancer 
incidence and mortality rates compared to more frequent tests.
292,293
  
Another necessary study is to examine how much the “ever screened participation rate” has 
changed over the years. As mentioned earlier, the definition of a triennial participation rate is 
somewhat arbitrary because the optimal screening interval is uncertain. What is clear then is that 
women who have never had a Pap test are at risk. It is important to understand the characteristics 
of those who have never participated (“unscreened women”) and find ways to encourage them to 
screen. This is probably more important than increasing the retention of those who have already 
been active in the program, even if these participants are not compliant with clinical guidelines. 
Allocating resources to reach unscreened women is an important first step towards increasing 
initial participation and reducing cervical cancer mortality.   
There is an ongoing debate on how screening intervals should be defined. As well 
increasing cervical screening participation as defined by a specific time frame seems to be a 
discussed frequently. It does not seem obvious what the optimal recall schedule really is, a fact 
demonstrated by changing guidelines in Saskatchewan and indeed across Canada. If PPCC’s 
main priority continues to be about increasing the participation rate, then this analysis suggests 
that a more consistent message may need to be sent in invitation and recall letters. Further in the 
context of organized screening, efforts to improve the quality of testing may be as or more 
important to detecting cancers early than efforts to increase programmatic participation.  
6.0 Concluding remarks 
         This study evaluated overall and age-specific Pap test participation and retention rates 
among women in Saskatchewan before and after the PPCC was introduced. The PPCC has 
significantly altered screening behaviour in its target population. Participation spiked just after 
program inception in 2003 thereafter steadily declining to 60.9% in 2009-2011 below the 
provincial rate before program inception. Participation was higher among younger women. 
Among those who participated, rural women were less likely to participate in cervical cancer 
screening compared to their urban counterparts. Urban residents in higher income neighborhoods 
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were more likely to participate and return to screen and a gradient of increasing uptake was 
observed across increasing income quintiles. Older women were more likely to follow-up on an 
abnormal-low result compared to younger women.  
       This analysis based on the conceptual framework helped clarify the roles of factors 
influencing participation at the system and client levels. Findings suggest that invitation letters 
sent by the organized cervical cancer screening program helped improve participation. 
Subsequent declines were partly driven by the mixed messaging inherent in result and recall 
letters (system-level). Participation and retention declines can also be partly attributed to the 
attitude and behaviour of the younger women (client-level). These client attitudes can potentially 
be influenced by physician attitudes and training. 
         Further work predicated on the availability of accurate provider-level data is necessary to 
clarify the role of the physician in guiding client participation. Research within the context of the 
conceptual framework is recommended to further elucidate system and client factors influencing 
participation, retention and testing patterns.  
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APPENDIX I  
THE PPCC CHRONOLOGY 
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APPENDIX II  
PPCC SCREENING PAMPHLETS AND BROCHURES 
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APPENDIX III  
OPT-OUT BROCHURE AND INFORMATION 
 
137 
 
138 
 
APPENDIX IV  
PPCC EVALUATION LOGIC MODEL 
Overall goal of this program: The Prevention Program for Cervical Cancer  (PPCC) is a screening program of the Saskatchewan 
Cancer Agency dedicated to the prevention of cervical cancer.  PPCC provides education about cervical cancer and the benefits 
of screening, inform women when they are due for a Pat test, notify women of their Pap test results, and work with care 
providers to ensure appropriate follow-up of abnormal Pap test results 
  
  
Decrease mortality rate 
from cervical cancer 
Decrease the incidence 
rate of cervical cancer 
Decrease in disparities in cervical 
cancer incidence and mortality due to 
ethnicity geography and SES 
1. Increasing number of women who initiate a Pap test 
and are appropriately screened 
2. Increasing number of HP offering the  Pap test 
appropriately. 
 
 
1. Decrease in percentage of over-screened 
2. Decrease of inconclusive results 
Physician’s computers 
linkage will help to 
stop/reduce the over-
screening and increase 
the follow-up or initiate 
screens 
Increase the rate of 
earlier detection 
incidence rates (in situ) 
Every woman turning 18: 
1. Is entered in the data base using the health card number 
and address 
2. Initial letter of invitation is prepared and is sent 
3. Letter of invitation is sent to every eligible woman at the 
appropriate time 
The percentage or number 
of letters returned because 
of wrong address or woman 
having had a hysterectomy 
1. Initial letters were sent 
correctly 
2. Percentage of letters 
returned is diminishing 
Coverage of all eligible 
women  
Uptake of Pap test  
1. PPCC at the Saskatchewan Cancer Agency 
2. Saskatchewan Health Ministry  
3. Clients 
1. Letters are mailed 
2. The PPCC ISIS data base is maintained  
Accessing the service (Pap test) 
1. Woman seeks test (compliance) 
2. HP provides the test 
1. PPCC at the Saskatchewan Cancer Agency 
2. Saskatchewan Health Regions  
3. Physician associations 
4. Health care providers 
5. Clients 
 1. Women make an appointment for Pap test 
2. Availability of women’s physician 
3. Test is offered 
4. Pap test is done 
5. Partnership with family physician to offer 
tests 
6. Access a clinic to have a Pap test (such as 
Pap test month for opening all the clinics for 
test) 
1. Participation rates 
2. Retention rates 
Guidelines known and followed 
appropriately  
1. Summary of the guideline is posted on the 
website of Saskatchewan Cancer Agency 
2. HP continuing education on the PPCC 
guidelines  
1. Median timing for letters sent to women 
based on previous Pap test 
2. HP self-report of behaviours 
3. Number of Pap test performed in a year 
per HP  
4. Number and timing of Pap tests following 
abnormal test or unsatisfactory test by HP 
1. Guidelines are disseminated to HP and 
followed by HP 
2. Letters are sent according to the guidelines 
      a. to women (invitation and result letter) 
      b. to HP (result letter and reminder fax or        
phone calls) 
 
1. Saskatchewan Cancer Agency 
2. Association of Family Physicians 
3. College of Medicine for students’ education 
4. Health Regions 
Education: Education and 
media campaign to promote:  
1. The uptake of Pap test 
2. The importance of the test 
 
1. Promotion of the early 
detection through Pap test 
2. Education through family 
physician and school of 
medicine 
SK eligible women (age 18-69) screened appropriately 
Long term 
outcomes  
Components 
Indicators  
Activities 
Resources  
Process/outputs 
Short-term 
outcomes 
 
  
1
3
8
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Accurate results with timely 
notification  
Long term 
outcomes  
Components 
Indicators  
Activities 
Resources  
Process/outputs 
Short-term 
outcomes 
Follow-up of abnormal screens 
and monitoring  
1. HP is sampling with quality 
     a. scrape at cervix right point (anatomy) 
     b. right procedure performed to prepare the slides 
2. Pathologist examines and reads the slides accurately 
     a. sampling slide 
      b. reading slide 
      c. notification 
Saskatchewan Provincial labs 
Physician associations 
Health care providers 
PPCC at the Saskatchewan Cancer Agency 
1. Slide is prepared by HP with Pap sample 
2. Performing analysis of slides 
3. Physician technical training on making sampling and slides 
4. Trainings for pathologist 
5. Provincial lab technical assistant training 
6. PPCC is notified in a timely manner 
1. Specimen adequacy rates 
2. Cytology turnaround time 
3. Cytology-histology agreement 
4. Pre-cancer detection rates 
 
 
 
 
 
1. Specimen adequacy rates increased 
2. Cytology turnaround time reduced 
3. Cytology-histology agreement increased 
4. Pre-cancer detection rates increased 
5. Specificity of test increased 
 
 
Number or percentage of women who 
get a second screen after abnormal or 
inconclusive results 
 
1. Abnormal results are received by PPCC 
2. Using ISIS data system from SPBC to enter screening data 
3. A letter is sent to notify woman 
4. A fax is sent to notify HP 
5. A phone call to notify HP 
PPCC at Saskatchewan Cancer Agency 
Health care providers 
Clients 
1.  Abnormal screens generate a list of 
clients 
     a. Entering results  b. Letter notification 
2. Notify HP to ask women to return to 
give a repeat Pap test 
3. Abnormal-high result will be referred to 
gynecologist for colposcopy and biopsy 
4.Normal result will be referred back to 
regular stream 
 
1. Repeat Pap test rates 
2. Biopsy rates 
3. Colposcopy follow-up rates 
1. The percentage of women who have 
a clear Pap test decreases 
2. Women are referred to colposcopy in 
a timely fashion 
Decrease in time from confirmed 
abnormal result to a colposcopy exam  
 
 
    
  
1
3
9
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APPENDIX V  
CLINICAL GUIDELINES 
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APPENDIX VI 
 ETHICS APPROVAL 
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